var title_f19_48_20224="Nailfold infarction in RV 1";
var content_f19_48_20224=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F61231&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F61231&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Isolated nailfold infarct",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 329px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Nailfold infarctions such as this are generally asymptomatic and not necessarily associated with systemic, necrotizing forms of rheumatoid vasculitis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of John Stone, MD, MPH.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_48_20224=[""].join("\n");
var outline_f19_48_20224=null;
var title_f19_48_20225="Exercise test ST seg changes";
var content_f19_48_20225=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F56740&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F56740&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Exercise induced ST segment depression",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 406px; height: 156px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Computer averaging shows the degree of ST segment depression (noted in mm below each QRS complex) in lead V6 prior to, during, and after exercise. Both horizontal and downsloping ST segment depressions are observed.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_48_20225=[""].join("\n");
var outline_f19_48_20225=null;
var title_f19_48_20226="Mucous membrane pemphigoid lip";
var content_f19_48_20226=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F52208&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F52208&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Mucous membrane pemphigoid",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Irregular erosions and a blister on the mucosal surface of the lip.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_48_20226=[""].join("\n");
var outline_f19_48_20226=null;
var title_f19_48_20227="Cutaneous squamous cell carcinoma - leg";
var content_f19_48_20227=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F52178&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F52178&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Cutaneous squamous cell carcinoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    An erythematous scaly papule is present on the lower leg.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_48_20227=[""].join("\n");
var outline_f19_48_20227=null;
var title_f19_48_20228="Belimumab: Patient drug information";
var content_f19_48_20228=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Belimumab: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/31/37365?source=see_link\">",
"     see \"Belimumab: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F12603131\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Benlysta&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F13243915\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Benlysta&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F12624690\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F12624691\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691946",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat lupus.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F12624611\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3378100",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to belimumab or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F12624613\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697596",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad infections have been reported with use of this drug. If you have any infection, are taking antibiotics now or in the recent past, or have many infections, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697571",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Make sure you are up to date with all your vaccines.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3432324",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a history of cancer, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697307",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have mental illness, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697613",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before getting any vaccines. Use with this drug may either raise the chance of an infection or make the vaccine not work as well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F12624766\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Fever, chills, itching, hives, chest pain or pressure, or shortness of breath when drug is given. Other drugs may be given to avoid these.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698315",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may have more chance of getting an infection. Wash hands often. Stay away from people with infections, colds, or flu.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698162",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to sleep.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698261",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698328",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Unsafe allergic effects may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F12624615\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699075",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of low mood (depression), thoughts of killing yourself, nervousness, emotional ups and downs, thinking that is not normal, anxiety, or lack of interest in life.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698626",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F12624693\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695989",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein over a period of time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694377",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Acetaminophen and diphenhydramine may be given before this drug to lower fever and chills.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F12624616\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16480 Version 19.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-89.32.226.102-FB51BAF4EE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_48_20228=[""].join("\n");
var outline_f19_48_20228=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12603131\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13243915\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12624690\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12624691\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12624611\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12624613\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12624766\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12624615\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12624693\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12624616\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?36/31/37365?source=related_link\">",
"      Belimumab: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_48_20229="Microbiology of enterococci";
var content_f19_48_20229=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Microbiology of enterococci",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/48/20229/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/48/20229/contributors\">",
"     Barbara E Murray, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/48/20229/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/48/20229/contributors\">",
"     Daniel J Sexton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/48/20229/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/48/20229/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?19/48/20229/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 2, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of the characteristic features of enterococci (formerly called group D streptococci) have been recognized for close to 100 years, including their presence in feces and sewage, their ability to cause endocarditis and urinary tract infections (UTIs), and their ability to survive harsh environmental conditions including drying, high temperatures, and exposure to some antiseptics [",
"    <a class=\"abstract\" href=\"UTD.htm?19/48/20229/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The common name enterococcus, derived from the French \"ent&eacute;rocoque\" used in an 1899 publication, points out that these bacteria are cocci of intestinal (enteric) origin, and the 1906 use of Streptococcus faecalis and the 1919 use of Streptococcus faecium also emphasized their presence in feces.",
"   </p>",
"   <p>",
"    Subsequent studies confirmed these early observations. Most humans and animals have enterococci in their intestinal tract; the counts in humans often range from 10(5) to 10(7) bacteria per gram of stool.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Enterococci, particularly Enterococcus faecalis, are a common cause of endocarditis (5 to 15 percent of community-acquired endocarditis and up to 30 percent of nosocomially-acquired endocarditis) and can be a common cause of nosocomial urinary tract infections (being recovered from up to 15 to 20 percent of UTIs in the hospital setting) [",
"      <a class=\"abstract\" href=\"UTD.htm?19/48/20229/abstract/3,4\">",
"       3,4",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MICROBIOLOGY CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Enterococci are gram-positive cocci that form short to medium length chains. In the 1930s, Lancefield devised a serologic typing system that classified enterococci as group D streptococci, along with some organisms (eg, Streptococcus gallolyticus, formerly S. bovis) that differed from enterococci in a number of other features. In 1937, Sherman divided streptococci into the pyogenic, viridans, lactic, and enterococcal groups. Enterococci were characterized by the following features:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Their reaction with group D antiserum",
"     </li>",
"     <li>",
"      Their ability to grow in high salt, at 10&ordm;C and 40&ordm;C, and at high pH",
"     </li>",
"     <li>",
"      Their ability to survive exposure to 60&ordm;C for 30 minutes",
"     </li>",
"     <li>",
"      Their ability to hydrolyze esculin in the presence of bile.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the ensuing 45 to 50 years, enterococci continued to be taxonomically classified in the genus Streptococcus. However, it was recognized by some authorities that these organisms had a number of distinguishing features, suggesting that the classification might be incorrect. In the mid-1980s, with advances in taxonomic techniques based upon nucleic acid analyses, it was proposed that S. faecalis and S. faecium be removed from the genus Streptococcus, transferred to a new genus, Enterococcus, and reclassified as E. faecalis and E. faecium, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?19/48/20229/abstract/5\">",
"     5",
"    </a>",
"    ]. Subsequently, other enterococcal species were also reclassified from the genus Streptococcus to the genus Enterococcus; a number of new species have also been recognized.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Problems with classification",
"    </span>",
"    &nbsp;&mdash;&nbsp;The characteristic features of enterococci as being bile esculin positive, reactive with group D antiserum, and able to grow in 6.5 percent sodium chloride were used by clinical laboratories for decades to distinguish enterococci from other catalase-negative gram-positive cocci. However, some problems arise with the use of these criteria. As an example, the presence of group D antigen can be difficult to detect in some enterococcal isolates. In addition, other organisms such as lactococci also can grow in high salt",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    be bile esculin positive; however, lactococci do not grow (or grow very slowly) at 45&ordm;C.",
"   </p>",
"   <p>",
"    Two other genera that share a number of biochemical features with enterococci, including their ability to produce the group D antigen, are Pediococcus and Leuconostoc, which can also grow at 45&ordm;C. These organisms are intrinsically",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    resistant, which was a reliable distinguishing trait prior to the emergence of vancomycin resistant enterococci (VRE). These genera are now best distinguished from VRE by the addition of tests for production of pyrrolidonyl arylamidase (PYR) and leucine aminopeptidase (LAP). Expected results are:",
"    <span class=\"nowrap\">",
"     +/+",
"    </span>",
"    with enterococci;",
"    <span class=\"nowrap\">",
"     -/+",
"    </span>",
"    for Pediococcus; and",
"    <span class=\"nowrap\">",
"     -/-",
"    </span>",
"    for Leuconostoc; Leuconostoc also produce gas from glucose [",
"    <a class=\"abstract\" href=\"UTD.htm?19/48/20229/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Identification at the species level",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many laboratories do not identify enterococci to the species level. Prior to the emergence of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    resistance, the majority of clinical enterococcal isolates were E. faecalis (85 to 90 percent), but the incidence of E. faecium in the United States has increased (now about 38 percent of enterococcal isolates), coincident with emergence of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/51/13112?source=see_link\">",
"     ampicillin",
"    </a>",
"    and vancomycin resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?19/48/20229/abstract/7\">",
"     7",
"    </a>",
"    ]. Although commercial kits for E. faecalis are generally reliable, commercial strips and kits for non-E. faecalis have been less reliable.",
"   </p>",
"   <p>",
"    With the increase in non-faecalis (primarily E. faecium) and the increased attention paid to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    resistant organisms, including E. gallinarum and E. casseliflavus, there is renewed interest in identifying these organisms. One reason for this interest is related to species-specific antimicrobial resistance differences that may not be apparent from routine antibiograms.",
"   </p>",
"   <p>",
"    For example, E. faecium isolates have, as a species characteristic, moderately high level resistance (MICs, ~250",
"    <span class=\"nowrap\">",
"     mcg/mL)",
"    </span>",
"    to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/35/34352?source=see_link\">",
"     tobramycin",
"    </a>",
"    , which prevents synergism of tobramycin with beta-lactams. Since this trait will not be detected by the clinical laboratory, use of tobramycin for endocarditis would require identification of the infecting organism to the species level. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/37/20058?source=see_link&amp;anchor=H11#H11\">",
"     \"Antimicrobial therapy of native valve endocarditis\", section on 'Enterococci'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Another reason is that the appearance of a non-faecalis, non-faecium species in different patients may be a clue to an outbreak secondary to nosocomial spread. The presence of multiple isolates of an unusual species from a single patient may also serve as a clue to relapse from an underlying focus (eg, renal abscess, endocarditis) rather than reinfection by a new organism.",
"   </p>",
"   <p>",
"    Enterococcal species were traditionally distinguished based upon results from a complex set of biochemical reactions, including fermentation of carbohydrates, hydrolysis of arginine, tolerance to tellurite, and motility and pigmentation:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Tellurite tolerance with production of black colonies and utilization of pyruvate are characteristic of E. faecalis",
"     </li>",
"     <li>",
"      The primary motile species are E. casseliflavus (E. flavescens) and E. gallinarum; yellow pigment is produced by E. casseliflavus and E. mundtii.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Motility and pigment are particularly useful for distinguishing E. casseliflavus and E. gallinarum from E. faecium, which can be misidentified by kits that do not include these tests. However, occasional isolates display atypical reactions.",
"   </p>",
"   <p>",
"    There are a number of difficulties with identification of enterococci to the species level. These include the necessity to perform multiple reactions, the analysis of which is best performed by computer application, and the difficulty in identifying enterococci with atypical phenotypic characteristics [",
"    <a class=\"abstract\" href=\"UTD.htm?19/48/20229/abstract/8\">",
"     8",
"    </a>",
"    ]. Genetic methods have largely replaced these biochemical tests for species identification. These include gene probes [",
"    <a class=\"abstract\" href=\"UTD.htm?19/48/20229/abstract/9,10\">",
"     9,10",
"    </a>",
"    ], polymerase chain reaction for specific genes or intergenic ribosomal PCR [",
"    <a class=\"abstract\" href=\"UTD.htm?19/48/20229/abstract/11,12\">",
"     11,12",
"    </a>",
"    ], and analysis of DNA relatedness [",
"    <a class=\"abstract\" href=\"UTD.htm?19/48/20229/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    On a practical level, most E. faecalis isolates are susceptible to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/51/13112?source=see_link\">",
"     ampicillin",
"    </a>",
"    but resistant to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/17/34068?source=see_link\">",
"     quinupristin-dalfopristin",
"    </a>",
"    , whereas most clinical E. faecium isolates are resistant to ampicillin yet susceptible to quinupristin-dalfopristin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     ANTIBIOTIC RESISTANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Enterococci come well equipped with a variety of intrinsic (ie, naturally occurring) antibiotic resistances. They are also capable of acquiring new resistance genes",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    mutations, particularly after exposure to antibiotics. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/56/26506?source=see_link\">",
"     \"Mechanisms of antibiotic resistance in enterococci\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    E. faecium isolates resistant to antibiotics have been recovered from commercial chicken and meat products in the United States. Two studies, for example, reported",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/17/34068?source=see_link\">",
"     quinupristin-dalfopristin",
"    </a>",
"    -resistant E. faecium in up to 78 percent of isolates from the poultry production environment [",
"    <a class=\"abstract\" href=\"UTD.htm?19/48/20229/abstract/13\">",
"     13",
"    </a>",
"    ] and 58 percent of chicken carcasses purchased in supermarkets from four states in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?19/48/20229/abstract/14\">",
"     14",
"    </a>",
"    ]. In the latter report, such resistant organisms were cultured in 3 of 334 (0.9 percent) stool specimens from outpatients [",
"    <a class=\"abstract\" href=\"UTD.htm?19/48/20229/abstract/14\">",
"     14",
"    </a>",
"    ]. In Europe, E. faecium resistant to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    have been identified frequently in food animals, although VRE belonging to clones common in food animal feces rarely have been found to infect humans.",
"   </p>",
"   <p>",
"    It is unclear whether the ingestion of these organisms leads to persistent intestinal carriage in humans. This issue was addressed in a study in which 12 healthy volunteers were fed glycopeptide and streptogramin-resistant E. faecium strains recovered from chickens or pork [",
"    <a class=\"abstract\" href=\"UTD.htm?19/48/20229/abstract/15\">",
"     15",
"    </a>",
"    ]. The strains were detectable in the stool of 8 of the 12 volunteers at one week, 1 of 12 at two weeks, and none at five weeks. This observation illustrates the potential for spread of these organisms along with their resistance genes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Nosocomial infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Enterococci are the second to third most common organism recovered from hospital-acquired (nosocomial) infections, particularly in more severely ill patients who have been hospitalized for long periods of time",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    have received multiple antibiotics [",
"    <a class=\"abstract\" href=\"UTD.htm?19/48/20229/abstract/4,16\">",
"     4,16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/4/27721?source=see_link\">",
"     \"Epidemiology, prevention and control of vancomycin-resistant enterococci\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Until the appearance of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    resistance, E. faecalis accounted for 85 to 90 percent of enterococcal isolates and E. faecium for &le;10 percent. However, a significant proportion of enterococci are E. faecium that have been implicated in up to 40 percent of bloodstream isolates in high risk populations such as liver or stem cell transplant recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?19/48/20229/abstract/17,18\">",
"     17,18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The prominence of enterococci in the hospital setting has been assumed to be related in large part to their many antimicrobial resistances, which allow them to survive, proliferate, and fill the void when antibiotic-susceptible organisms are eliminated [",
"    <a class=\"abstract\" href=\"UTD.htm?19/48/20229/abstract/19\">",
"     19",
"    </a>",
"    ]. However, data showing that most clinical isolates in the US belong to a single clonal cluster (CC17) of related multi-locus sequence types (MLST) and have or express genes that animal and community human fecal isolates do not have, suggest that this clone is not just more resistant but also more capable of colonizing, spreading",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    causing infection [",
"    <a class=\"abstract\" href=\"UTD.htm?19/48/20229/abstract/20-22\">",
"     20-22",
"    </a>",
"    ]",
"   </p>",
"   <p>",
"    As survivors in the face of antibiotics use [",
"    <a class=\"abstract\" href=\"UTD.htm?19/48/20229/abstract/23\">",
"     23",
"    </a>",
"    ], enterococci have an enhanced opportunity to cause infection, particularly in a patient with altered immune defenses",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    multiple potential portals of entry. However, enterococci also have intrinsic factors such as a number of potential adhesin genes, which may explain the propensity of enterococci to cause endocarditis.",
"   </p>",
"   <p>",
"    Once enterococci cause infection, their antibiotic resistances can create even greater dilemmas. Our worst therapeutic problems arise when a multidrug-resistant hospital-acquired enterococcus causes endocarditis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/62/14314?source=see_link\">",
"     \"Treatment of enterococcal infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H90634767\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Enterococci (formerly called group D streptococci) are gram-positive cocci of intestinal origin that usually form short chains and a common cause of endocarditis and nosocomial infections. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Microbiologic characteristics of enterococci include reactivity with group D antiserum, ability to grow in high salt, at 10&ordm;C and 40&ordm;C, and at high pH, and survival at 60&ordm;C for 30 minutes. They hydrolyze esculin in the presence of bile and produce pyrrolidonyl arylamidase (PYR). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Microbiology classification'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Species differentiation, traditionally based on results from a complex set of biochemical reactions but more recently on DNA based testing, is important as species-specific antimicrobial resistance differences can affect therapeutic decisions. &nbsp;The identification of non-faecium, non-faecalis species can be helpful in detecting nosocomial outbreaks or relapsing infection. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Identification at the species level'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most E. faecalis isolates are susceptible to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/51/13112?source=see_link\">",
"       ampicillin",
"      </a>",
"      but resistant to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/17/34068?source=see_link\">",
"       quinupristin-dalfopristin",
"      </a>",
"      . Most clinical E. faecium isolates are resistant to ampicillin, susceptible to quinupristin-dalfopristin, and have moderately high level resistance to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/35/34352?source=see_link\">",
"       tobramycin",
"      </a>",
"      ; in the United States, most clinical E. faecium are resistant to moderate to high levels of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"       vancomycin",
"      </a>",
"      . E. gallinarum and E. casseliflavus are resistant to low levels of vancomycin. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Identification at the species level'",
"      </a>",
"      above.). &nbsp;",
"     </li>",
"     <li>",
"      Enterococci resistant to antibiotics have been recovered from commercial chicken and meat products in the United States, but it is unclear whether the ingestion of these organisms leads to persistent intestinal carriage in humans. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Antibiotic resistance'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/56/26506?source=see_link\">",
"       \"Mechanisms of antibiotic resistance in enterococci\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Their many antimicrobial resistances, which allow them to survive, proliferate, and fill the void when antibiotic-susceptible organisms are eliminated, may contribute to the frequency of enterococci in nosocomial infections. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Nosocomial infection'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20229/abstract/1\">",
"      Murray BE. The life and times of the Enterococcus. Clin Microbiol Rev 1990; 3:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20229/abstract/2\">",
"      Wade JJ. Enterococcus faecium in hospitals. Eur J Clin Microbiol Infect Dis 1997; 16:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20229/abstract/3\">",
"      Gross PA, Harkavy LM, Barden GE, Flower MF. The epidemiology of nosocomial enterococcal urinary tract infection. Am J Med Sci 1976; 272:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20229/abstract/4\">",
"      Emori TG, Gaynes RP. An overview of nosocomial infections, including the role of the microbiology laboratory. Clin Microbiol Rev 1993; 6:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20229/abstract/5\">",
"      Schleifer KH, Kilpper-Balz R. Transfer of Streptococcus faecalis and Streptococcus faecium to the genus Enterococcus nom. rev. as Enterococcus faecalis comb. nov. and Enterococcus faecium comb. Int J Syst Bacteriol 1984; 34:31.",
"     </a>",
"    </li>",
"    <li>",
"     Teixeira LM, Carvalho MS, Facklam RR. Enterococcus. In: Manual of Clinical Microbiology, Murray PR, Baron EJ, Jorgensen JH, LLandry ML, Pfaller MA (Eds), ASM Press, Washington, DC 2007.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20229/abstract/7\">",
"      Hidron AI, Edwards JR, Patel J, et al. NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007. Infect Control Hosp Epidemiol 2008; 29:996.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20229/abstract/8\">",
"      Teixeira LM, Facklam RR, Steigerwalt AG, et al. Correlation between phenotypic characteristics and DNA relatedness within Enterococcus faecium strains. J Clin Microbiol 1995; 33:1520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20229/abstract/9\">",
"      Coque TM, Murray BE. Identification of Enterococcus faecalis strains by DNA hybridization and pulsed-field gel electrophoresis. J Clin Microbiol 1995; 33:3368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20229/abstract/10\">",
"      Singh KV, Coque TM, Weinstock GM, Murray BE. In vivo testing of an Enterococcus faecalis efaA mutant and use of efaA homologs for species identification. FEMS Immunol Med Microbiol 1998; 21:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20229/abstract/11\">",
"      Tyrrell GJ, Bethune RN, Willey B, Low DE. Species identification of enterococci via intergenic ribosomal PCR. J Clin Microbiol 1997; 35:1054.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20229/abstract/12\">",
"      Depardieu F, Perichon B, Courvalin P. Detection of the van alphabet and identification of enterococci and staphylococci at the species level by multiplex PCR. J Clin Microbiol 2004; 42:5857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20229/abstract/13\">",
"      Hayes JR, McIntosh AC, Qaiyumi S, et al. High-frequency recovery of quinupristin-dalfopristin-resistant Enterococcus faecium isolates from the poultry production environment. J Clin Microbiol 2001; 39:2298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20229/abstract/14\">",
"      McDonald LC, Rossiter S, Mackinson C, et al. Quinupristin-dalfopristin-resistant Enterococcus faecium on chicken and in human stool specimens. N Engl J Med 2001; 345:1155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20229/abstract/15\">",
"      S&oslash;rensen TL, Blom M, Monnet DL, et al. Transient intestinal carriage after ingestion of antibiotic-resistant Enterococcus faecium from chicken and pork. N Engl J Med 2001; 345:1161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20229/abstract/16\">",
"      Schaberg DR, Culver DH, Gaynes RP. Major trends in the microbial etiology of nosocomial infection. Am J Med 1991; 91:72S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20229/abstract/17\">",
"      Mikulska M, Del Bono V, Raiola AM, et al. Blood stream infections in allogeneic hematopoietic stem cell transplant recipients: reemergence of Gram-negative rods and increasing antibiotic resistance. Biol Blood Marrow Transplant 2009; 15:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20229/abstract/18\">",
"      Bedini A, Codeluppi M, Cocchi S, et al. Gram-positive bloodstream infections in liver transplant recipients: incidence, risk factors, and impact on survival. Transplant Proc 2007; 39:1947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20229/abstract/19\">",
"      Suppola JP, Volin L, Valtonen VV, Vaara M. Overgrowth of Enterococcus faecium in the feces of patients with hematologic malignancies. Clin Infect Dis 1996; 23:694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20229/abstract/20\">",
"      Rice LB, Carias L, Rudin S, et al. A potential virulence gene, hylEfm, predominates in Enterococcus faecium of clinical origin. J Infect Dis 2003; 187:508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20229/abstract/21\">",
"      Nallapareddy SR, Weinstock GM, Murray BE. Clinical isolates of Enterococcus faecium exhibit strain-specific collagen binding mediated by Acm, a new member of the MSCRAMM family. Mol Microbiol 2003; 47:1733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20229/abstract/22\">",
"      Leavis HL, Bonten MJ, Willems RJ. Identification of high-risk enterococcal clonal complexes: global dispersion and antibiotic resistance. Curr Opin Microbiol 2006; 9:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20229/abstract/23\">",
"      Sillanp&auml;&auml; J, Prakash VP, Nallapareddy SR, Murray BE. Distribution of genes encoding MSCRAMMs and Pili in clinical and natural populations of Enterococcus faecium. J Clin Microbiol 2009; 47:896.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3160 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-200.167.4.114-B39C775BF0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_48_20229=[""].join("\n");
var outline_f19_48_20229=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H90634767\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MICROBIOLOGY CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Problems with classification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Identification at the species level",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      ANTIBIOTIC RESISTANCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Nosocomial infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H90634767\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/37/20058?source=related_link\">",
"      Antimicrobial therapy of native valve endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/4/27721?source=related_link\">",
"      Epidemiology, prevention and control of vancomycin-resistant enterococci",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/56/26506?source=related_link\">",
"      Mechanisms of antibiotic resistance in enterococci",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/62/14314?source=related_link\">",
"      Treatment of enterococcal infections",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_48_20230="Forward step up PI";
var content_f19_48_20230=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F69481&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F69481&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Forward step up",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 411px; height: 515px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Place left foot onto a step, then step up with right foot. Move left foot back down to floor then step down with right. Repeat this sequence 10 times then change order of feet (step first with the left, followed by the right); this is one set. Perform three sets.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_48_20230=[""].join("\n");
var outline_f19_48_20230=null;
var title_f19_48_20231="Metronidazole (systemic): Pediatric drug information";
var content_f19_48_20231=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Metronidazole (systemic): Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?34/7/34936?source=see_link\">",
"    see \"Metronidazole (systemic): Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?18/48/19205?source=see_link\">",
"    see \"Metronidazole (systemic): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F8770965\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F8770969\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Flagyl&reg;;",
"     </li>",
"     <li>",
"      Flagyl&reg; 375;",
"     </li>",
"     <li>",
"      Flagyl&reg; ER",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F8770970\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Metronidazole&reg;;",
"     </li>",
"     <li>",
"      Flagyl&reg;;",
"     </li>",
"     <li>",
"      Florazole&reg; ER",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F10529895\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Amebicide",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antibiotic, Anaerobic",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antiprotozoal",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F11443888\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Anaerobic infections:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Weight-directed dosing:",
"     </b>",
"     Oral, I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     PNA 0-28 days and &lt;1200 g: 7.5 mg/kg every 24-48 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     PNA &lt;7 days:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     1200-2000 g: 7.5 mg/kg/day given every 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &gt;2000 g: 15 mg/kg/day in divided doses every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     PNA &ge;7 days:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     1200-2000 g: 15 mg/kg/day in divided doses every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &gt;2000 g: 30 mg/kg/day in divided doses every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Age-directed dosing:",
"     </b>",
"     I.V.:",
"     <b>",
"      Note:",
"     </b>",
"     Postmenstrual age is the sum of gestational age (weeks) and postnatal age (weeks) (AAP, 2004). Dosing based on pharmacokinetic analysis and modeling of 32 preterm neonates (Suyagh, 2011).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Loading dose: 15 mg/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Maintenance dose:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Postmenstrual age &le;25 weeks: 7.5 mg/kg every 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Postmenstrual age 26-27 weeks: 10 mg/kg every 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Postmenstrual age 28-33 weeks: 7.5 mg/kg every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Postmenstrual age 34-44 weeks: 10 mg/kg every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Postmenstrual age &ge;45 weeks: 7.5 mg/kg every 6 hours",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F10529964\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?34/7/34936?source=see_link\">",
"      see \"Metronidazole (systemic): Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Infants and Children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Amebiasis: Oral: 35-50 mg/kg/day in divided doses every 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Other parasitic infections: Oral: 15-30 mg/kg/day in divided doses every 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Anaerobic infections: Oral, I.V.: 30 mg/kg/day in divided doses every 6 hours; maximum dose: 4 g/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     AAPC: Oral: 30 mg/kg/day divided every 6 hours for 7-10 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Helicobacter pylori",
"     </i>",
"     infection (has been used in combination with amoxicillin and bismuth subsalicylate): Oral: 15-20 mg/kg/day in 2 divided doses for 4 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Amebiasis: Oral: 500-750 mg every 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Anaerobic infections: Oral, I.V.: 30 mg/kg/day in divided doses every 6 hours; not to exceed 4 g/day;",
"     <b>",
"      Note:",
"     </b>",
"     Initial: 1 g I.V. loading dose may be administered",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     AAPC: Oral: 250-500 mg 3-4 times/day for 10-14 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Bacterial vaginosis or vaginitis due to",
"     <i>",
"      Gardnerella, Mobiluncus",
"     </i>",
"     : Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Regular release: 500 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Extended release: 750 mg once daily for 7 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Helicobacter pylori",
"     </i>",
"     infection: Oral: 250-500 mg 3 times/day in combination with at least one other agent active against",
"     <i>",
"      H. pylori",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Trichomoniasis: Oral: 500 mg every 12 hours for 7 days or 2 g as a single dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Surgical prophylaxis (colorectal): I.V. 15 mg/kg 1 hour prior to surgery; followed by 7.5 mg/kg 6 and 12 hours after initial dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosing adjustment in hepatic impairment:",
"     </b>",
"     50% to 67% decrease in dosage",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F8771210\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral: 375 mg [DSC]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Flagyl&reg; 375: 375 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infusion, premixed iso-osmotic sodium chloride solution: 500 mg (100 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 250 mg, 500 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Flagyl&reg;: 250 mg, 500 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, extended release, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Flagyl&reg; ER: 750 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F8770972\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes capsule, extended release tablet",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F10529984\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral: Administer on an empty stomach; may administer with food if GI upset occurs",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Parenteral: Administer I.V. by slow intermittent infusion over 30-60 minutes at a final concentration for administration of 5-8 mg/mL. Avoid contact of drug solution with equipment containing aluminum.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F8771128\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W, LR, NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Acyclovir, allopurinol, amifostine, amiodarone, anidulafungin, bivalirudin, caspofungin, cefepime, ciprofloxacin, cisatracurium, cyclophosphamide, cyclosporine, dexmedetomidine, diltiazem, dimenhydrinate, docetaxel, dopamine, doripenem, doxapram, doxorubicin liposome, enalaprilat, esmolol, etoposide phosphate, fenoldopam, fentanyl, fluconazole, foscarnet, gemcitabine, granisetron, heparin, hetastarch in lactate electrolyte injection (Hextend&reg;), hydromorphone, labetalol, levofloxacin, linezolid, lorazepam, magnesium sulfate, melphalan, meperidine, methylprednisolone sodium succinate, midazolam, milrinone, morphine, nicardipine, oxytocin, palonosetron, piperacillin/tazobactam, remifentanil, sargramostim, tacrolimus, teniposide, theophylline, thiotepa, vasopressin, vinorelbine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Amphotericin B cholesteryl sulfate complex, aztreonam, drotrecogin alpha, filgrastim, meropenem, pemetrexed.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Dopamine, doxapram, pantoprazole, warfarin.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F10529926\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Injection: Store at 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F)  and protect from light during storage. Keep in overwrap until ready to use. Do not refrigerate; crystal formation may occur; crystals redissolve on warming to room temperature. Prolonged exposure to light will cause a darkening of the product; however, short-term exposure to normal room light does not adversely affect metronidazole stability. Direct sunlight should be avoided. Stability of parenteral admixture at room temperature (25&deg;C); out of overwrap stability: 30 days.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablets: Store below 25&deg;C (77&deg;F)  and protect from light.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablets, extended release: Store in a dry place at 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F).",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F10529909\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of susceptible amebiasis [intestinal (dysentery) or liver abscess] [Oral: FDA approved in pediatric patients (age not specified) and adults; parenteral: FDA approved in adults]; treatment of susceptible anaerobic bacterial and protozoal infections in the following conditions: Giardiasis, symptomatic and asymptomatic trichomoniasis; skin and skin structure infections, bone and joint infections, CNS infections, endocarditis, gynecological infections, intra-abdominal infections, respiratory tract (lower) infections, systemic anaerobic bacterial infections; surgical prophylaxis (colorectal); treatment of antibiotic-associated pseudomembranous colitis (AAPC) caused by",
"     <i>",
"      C. difficile",
"     </i>",
"     (Oral, parenteral: FDA approved in adults)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F8770967\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       MetroNIDAZOLE may be confused with mebendazole, meropenem, metFORMIN, methotrexate, metoclopramide, miconazole",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F8771039\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Flattening of the T-wave, flushing, syncope",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Aseptic meningitis, ataxia, confusion, coordination impaired, depression, dizziness, encephalopathy, fever, headache, insomnia, irritability, seizure, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Erythematous rash, pruritus, Stevens-Johnson syndrome, toxic epidermal necrolysis, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Disulfiram-like reaction, dysmenorrhea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Anorexia, abdominal cramping, constipation, diarrhea, epigastric distress, furry tongue, glossitis, nausea, pancreatitis (rare), proctitis, stomatitis, unusual/metallic taste, vomiting, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Cystitis, darkened urine (rare), dyspareunia, dysuria, incontinence, libido decreased, pelvic pressure, polyuria, vaginal dryness, vaginitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Neutropenia (reversible), thrombocytopenia (reversible, rare)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Thrombophlebitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Dysarthria, peripheral neuropathy, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Optic neuropathy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Nasal congestion, pharyngitis, rhinitis, sinusitis, pharyngitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Flu-like syndrome, joint pains resembling serum sickness, moniliasis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F10529910\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to metronidazole, nitroimidazole derivatives, or any component; 1st trimester of pregnancy",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F10529913\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with hepatic impairment due to potential accumulation; reduce dosage if hepatic impairment severe. Use with caution in patients with or history of blood dyscrasias; leukopenia has occurred. Use with caution in patients with CNS disease; metronidazole injection should be used with caution in patients receiving corticosteroids or patients predisposed to edema (eg, heart failure or other sodium-retaining conditions); injection contains 28 mEq of sodium/g metronidazole.  For short-term therapy, dosage adjustment is not necessary in patients with moderate-to-severe renal insufficiency; a dosage reduction should be considered with longer-term therapy and severe renal failure (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute). Disulfiram-like reactions to ethanol have been reported with oral metronidazole; avoid alcoholic beverages during therapy Prolonged use may result in fungal or bacterial superinfection, including",
"     <i>",
"      C. difficile",
"     </i>",
"     -associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment. Candidiasis infection (known or unknown) may be more prominent during metronidazole treatment; antifungal treatment required.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F10529911\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Has been shown to be carcinogenic in rodents",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; aseptic meningitis, encephalopathy, seizures, and neuropathies (peripheral and optic) have been reported, especially with increased doses and chronic treatment; monitor and consider discontinuation of therapy if signs/symptoms occur. Use with caution in patients with a history of seizure disorder; consider reduced doses in patients who have noninfectious CNS disease.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F8771042\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2C9 (weak), CYP3A4 (moderate)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F8771043\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): MetroNIDAZOLE (Systemic) may enhance the adverse/toxic effect of Alcohol (Ethyl). A disulfiram-like reaction may occur.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Avanafil: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Avanafil.  Management: The maximum avanafil adult dose is 50 mg per 24-hour period when used together with a moderate CYP3A4 inhibitor.  Patients receiving such a combination should also be monitored more closely for evidence of adverse effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Antibiotics may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Bosutinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Budesonide (Systemic, Oral Inhalation): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Budesonide (Systemic, Oral Inhalation).  Management: Consider reducing the oral budesonide dose when used together with a CYP3A4 inhibitor.  This interaction is likely less severe with orally inhaled budesonide.  Monitor patients closely for signs/symptoms of corticosteroid excess.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Busulfan: MetroNIDAZOLE (Systemic) may increase the serum concentration of Busulfan.  Management: The toxic effects of busulfan may be greatly increased with concomitant use of metronidazole. This combination should probably be avoided when possible.  If these agents must be used together, increased monitoring for busulfan toxicity is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcineurin Inhibitors: MetroNIDAZOLE (Systemic) may decrease the metabolism of Calcineurin Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colchicine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Colchicine.  Management: Reduce colchicine dose as directed when using with a moderate CYP3A4 inhibitor, and increase monitoring for colchicine-related toxicity.  Use extra caution in patients with impaired renal and/or hepatic function.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Substrates: CYP3A4 Inhibitors (Moderate) may decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Disulfiram: May enhance the adverse/toxic effect of MetroNIDAZOLE (Systemic).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Eplerenone.  Management: When used concomitantly with moderate inhibitors of CYP3A4, eplerenone dosing recommendations may vary depending on international labeling. Consult appropriate labeling for specific recommendations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Everolimus: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Everolimus.  Management: Everolimus dose reductions are required for patients being treated for subependymal giant cell astrocytoma or renal cell carcinoma.  See prescribing information for specific dose adjustment and monitoring recommendations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     FentaNYL: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of FentaNYL.  Management: Monitor patients extra closely for several days following initiation of the combination, and fentanyl dosage reductions should be made as appropriate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluorouracil (Systemic): MetroNIDAZOLE (Systemic) may increase the serum concentration of Fluorouracil (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: May decrease the serum concentration of MetroNIDAZOLE (Systemic). MetroNIDAZOLE (Systemic) may increase the serum concentration of Fosphenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Halofantrine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Halofantrine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ifosfamide: CYP3A4 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Ifosfamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivabradine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ivabradine.  Management: In patients with a resting heart rate over 60 beats per minute receiving a moderate CYP3A4 inhibitor, ivabradine initiation at an adult dose of 2.5 mg twice daily may be considered.  Monitor heart rate closely under these circumstances.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ivacaftor.  Management: Decrease ivacaftor dose to 150 mg daily in patients also receiving moderate CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lomitapide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lurasidone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lurasidone.  Management: U.S. labeling: start at 20 mg/day and limit to max of 80 mg/day with moderate CYP3A4 inhibitor.  Canadian labeling: limit to max of 40 mg/day with moderate CYP3A4 inhibitor; avoid concomitant use of grapefruit products.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mebendazole: May enhance the adverse/toxic effect of MetroNIDAZOLE (Systemic). Particularly the risk for Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis may be increased.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mycophenolate: MetroNIDAZOLE (Systemic) may decrease the serum concentration of Mycophenolate. Specifically, metronidazole may decrease concentrations of the active metabolite of mycophenolate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PHENobarbital: May decrease the serum concentration of MetroNIDAZOLE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: MetroNIDAZOLE (Systemic) may increase the serum concentration of Phenytoin. Phenytoin may decrease the serum concentration of MetroNIDAZOLE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: CYP3A4 Inhibitors (Moderate) may decrease the metabolism of Pimecrolimus.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Propafenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ranolazine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ranolazine.  Management: Limit the ranolazine adult dose to a maximum of 500 mg twice daily in patients concurrently receiving moderate CYP3A4 inhibitors (e.g., diltiazem, verapamil, erythromycin, etc.).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salmeterol: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Salmeterol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saxagliptin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Saxagliptin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tipranavir: MetroNIDAZOLE (Systemic) may enhance the adverse/toxic effect of Tipranavir. A disulfiram-like reaction may occur due to the alcohol contained in tipranavir capsules.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Tolvaptan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 24 hours after cessation of antibacterial agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vilazodone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Vilazodone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): MetroNIDAZOLE (Systemic) may increase the serum concentration of Vitamin K Antagonists.  Management: Consider alternatives to concomitant therapy with these agents.  Monitor for increased INR/bleeding risk if metronidazole is initiated/dose increased, or decreased effects if metronidazole is discontinued/dose decreased.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zuclopenthixol: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Zuclopenthixol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F10529925\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Peak concentration is decreased and delayed when administered with food.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F8771018\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F8771019\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects have not been observed in animal reproduction studies. Metronidazole crosses the placenta and rapidly distributes into the fetal circulation. Although there have been a few reports of facial anomalies after",
"     <i>",
"      in utero",
"     </i>",
"     exposure, most studies have not found an increased risk of congenital abnormalities following maternal use of metronidazole during the first trimester of pregnancy. In studies that included women taking metronidazole during all trimesters of pregnancy, an increased risk of adverse fetal and neonatal outcomes has not been observed. Because metronidazole has been carcinogenic in some animal species, concern has been raised whether metronidazole should be used during pregnancy; however, a strong carcinogenic potential in humans has not been observed, including one study of prenatal exposure.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Metronidazole pharmacokinetics are similar between pregnant and nonpregnant patients.  Bacterial vaginosis has been associated with adverse pregnancy outcomes (including preterm labor); metronidazole is recommended for the treatment of symptomatic bacterial vaginosis in pregnant patients. Vaginal trichomoniasis has been also associated with adverse pregnancy outcomes (including preterm labor). Treatment may relieve symptoms and prevent further sexual transmission; however, metronidazole has not resulted in reduced perinatal morbidity and should not be used solely to prevent preterm delivery.  Some clinicians consider deferring therapy in asymptomatic women until &gt;37 weeks gestation. Use of oral metronidazole is contraindicated during the first trimester (per the FDA approved labeling). Consult current CDC guidelines for appropriate use in pregnant women.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F10529985\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     WBC count; observe for change in bowel movements (number, type of stools/day)",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F10529927\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reduced to a product which interacts with DNA to cause a loss of helical DNA structure and strand breakage, resulting in inhibition of protein synthesis and cell death in susceptible organisms",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F10529944\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Absorption: Oral: Well absorbed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: Excreted in breast milk; widely distributed into body tissues, fluids (including bile), liver, bone, pleural fluid, vaginal secretions, CSF, erythrocytes, and hepatic abscesses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: &lt;20%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: 30% to 60% in the liver to hydroxylated metabolite (60% to 80% bioactive), acetic acid metabolites, glucuronide, and sulfated conjugates",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life (increases with hepatic impairment):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neonates: 25-75 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children and Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Metronidazole: 6-12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Hydroxymetronidazole: 9.5-20 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak serum concentration: Within 1-2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Elimination: Excreted via the urine (20% as unchanged drug) and feces (6% to 15%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dialysis: Extensively removed by hemodialysis and peritoneal dialysis",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F10529987\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?18/48/19205?source=see_link\">",
"      see \"Metronidazole (systemic): Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May discolor urine dark or reddish brown; avoid alcohol; do not take alcohol for at least 48 hours after the last dose; may cause dry mouth",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F10529989\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Sodium content of 500 mg ready-to-use vial: 14 mEq",
"    </p>",
"   </div>",
"   <div class=\"block exp drugH1Div\" id=\"F8771213\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Extemporaneous Preparations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A 50 mg/mL oral suspension may be made with tablets and a 1:1 mixture of Ora-Sweet&reg; and Ora-Plus&reg;. Crush twenty-four 250 mg tablets in a mortar and reduce to a fine powder. Add small portions of the vehicle and mix to a uniform paste; mix while adding the vehicle in incremental portions to",
"     <b>",
"      almost",
"     </b>",
"     120 mL; transfer to a calibrated bottle, rinse mortar with vehicle, and add quantity of vehicle sufficient to make 120 mL. Label \"shake well\". Stable for 60 days at room temperature or refrigerated.",
"    </p>",
"    <div class=\"reference\">",
"     Allen LV Jr and Erickson MA 3rd, &ldquo;Stability of Ketoconazole, Metolazone, Metronidazole, Procainamide Hydrochloride, and Spironolactone in Extemporaneously Compounded Oral Liquids,&rdquo;",
"     <i>",
"      Am J Health Syst Pharm",
"     </i>",
"     , 1996, 53(17):2073-8.",
"     <span class=\"pubmed-id\">",
"      8870895",
"     </span>",
"    </div>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention, \"Sexually Transmitted Diseases Treatment Guidelines &minus; 2006,\"",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2006, 55(RR-11):1-100. Available at:",
"      <a href=\"file://www.cdc.gov/std/treatment/2006/rr5511.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/std/treatment/2006/rr5511.pdf",
"      </a>",
"      .",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Israel DM and Hassall E, \"Treatment and Long-Term Follow-Up of",
"      <i>",
"       Helicobacter pylori",
"      </i>",
"      -Associated Duodenal Ulcer Disease in Children,\"",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1993, 123(1):53-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/48/20231/abstract-text/8320625/pubmed\" id=\"8320625\" target=\"_blank\">",
"        8320625",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kelly CP, Pothoulakis C, and LaMont JT, \"",
"      <i>",
"       Clostridium difficile",
"      </i>",
"      Colitis,\"",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1994, 330(4):257-62.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/48/20231/abstract-text/8043060/pubmed\" id=\"8043060\" target=\"_blank\">",
"        8043060",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Oldenburg B and Speck WT, \"Metronidazole,\"",
"      <i>",
"       Pediatr Clin North Am",
"      </i>",
"      , 1983, 30(1):71-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/48/20231/abstract-text/6338471/pubmed\" id=\"6338471\" target=\"_blank\">",
"        6338471",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      \"Sexual Assault and the Adolescent. American Academy of Pediatrics Committee on Adolescence,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1994, 94(5):761-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/48/20231/abstract-text/7936916/pubmed\" id=\"7936916\" target=\"_blank\">",
"        7936916",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Suyagh M, Collier PS, Millership JS, et al, \"Metronidazole Population Pharmacokinetics in Preterm Neonates Using Dried Blood-Spot Sampling,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2011, 127(2):e367-74.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/48/20231/abstract-text/21220396/pubmed\" id=\"21220396\" target=\"_blank\">",
"        21220396",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16019 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-190.111.122.2-168C04E0CB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_48_20231=[""].join("\n");
var outline_f19_48_20231=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8770965\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8770969\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8770970\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10529895\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11443888\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10529964\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8771210\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8770972\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10529984\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8771128\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10529926\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10529909\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8770967\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8771039\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10529910\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10529913\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10529911\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8771042\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8771043\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10529925\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8771018\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8771019\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10529985\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10529927\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10529944\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10529987\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10529989\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8771213\">",
"      Extemporaneous Preparations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/16019\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/16019|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?34/7/34936?source=related_link\">",
"      Metronidazole (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?18/48/19205?source=related_link\">",
"      Metronidazole (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?13/25/13717?source=related_link\">",
"      Metronidazole (topical): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?0/5/95?source=related_link\">",
"      Metronidazole (topical): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/45/23252?source=related_link\">",
"      Metronidazole (topical): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_48_20232="Intestinal malrotation";
var content_f19_48_20232=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Intestinal malrotation",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/48/20232/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/48/20232/contributors\">",
"     Mary L Brandt, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/48/20232/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/48/20232/contributors\">",
"     Jonathan I Singer, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/48/20232/contributors\">",
"     George D Ferry, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/48/20232/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/48/20232/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?19/48/20232/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 4, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rotational anomalies occur as a result of an arrest of normal rotation of the embryonic gut. They are often associated with other gastrointestinal abnormalities, particularly those in which the intestines are located outside the coelomic cavity (eg, congenital diaphragmatic hernia or abdominal wall defects). However, intestinal malrotation can also occur in children and adults who have no associated anomalies.",
"   </p>",
"   <p>",
"    An overview of the presentation, diagnosis, and treatment of intestinal malrotation will be presented here. Congenital diaphragmatic hernia and abdominal wall defects are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/35/38454?source=see_link\">",
"     \"Obstetrical management of omphalocele\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rotational anomalies, which may or may not be symptomatic, are estimated to occur in between",
"    <span class=\"nowrap\">",
"     1/200",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     1/500",
"    </span>",
"    live births [",
"    <a class=\"abstract\" href=\"UTD.htm?19/48/20232/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Symptomatic malrotation is estimated to occur in",
"    <span class=\"nowrap\">",
"     1/6000",
"    </span>",
"    live births [",
"    <a class=\"abstract\" href=\"UTD.htm?19/48/20232/abstract/3\">",
"     3",
"    </a>",
"    ]. Traditionally, intestinal malrotation has been considered primarily a disease of infancy with infrequent occurrence beyond the first year of life. However, a series of 170 patients of all ages with intestinal malrotation managed at a single institution found the following age distribution [",
"    <a class=\"abstract\" href=\"UTD.htm?19/48/20232/abstract/4\">",
"     4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Infants under one year of age: 31 percent",
"     </li>",
"     <li>",
"      Children one to 18 years of age: 21 percent",
"     </li>",
"     <li>",
"      Adults over 18 years of age: 48 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, the prevalence of malrotation in children over one year of age and adults may be higher than previously thought.",
"   </p>",
"   <p>",
"    Between 30 and 62 percent of children who have intestinal malrotation have an associated anomaly (",
"    <a class=\"graphic graphic_table graphicRef72191 \" href=\"UTD.htm?16/22/16747\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/48/20232/abstract/5-8\">",
"     5-8",
"    </a>",
"    ]. Rotational defects are present in all children with diaphragmatic hernia, gastroschisis, and omphalocele. As many as 17 percent of children with duodenal atresia and 33 percent of children with jejunoileal atresia may have an associated malrotation [",
"    <a class=\"abstract\" href=\"UTD.htm?19/48/20232/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/55/31608?source=see_link\">",
"     \"Intestinal atresia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rotational anomalies occur as a result of an arrest of normal rotation of the embryonic gut. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/15/41205?source=see_link\">",
"     \"Overview of the development of the gastrointestinal tract\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    During the fourth to eighth week of embryonic development, the embryonic coelom, or cavity, cannot accommodate the rapidly expanding gastrointestinal (GI) tract. As a result, the primary intestinal loop buckles into the area of the yolk stalk, which will be the future umbilicus. The axis of this loop is the developing superior mesenteric artery (SMA). As the primary intestinal loop buckles out of the abdomen, it begins the normal rotation of the bowel by twisting 90 degrees counterclockwise (",
"    <a class=\"graphic graphic_figure graphicRef78643 \" href=\"UTD.htm?7/52/8007\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef68817 \" href=\"UTD.htm?12/60/13255\">",
"     figure 2",
"    </a>",
"    ). This initial rotation is driven by two factors [",
"    <a class=\"abstract\" href=\"UTD.htm?19/48/20232/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The proximal bowel (the \"prearterial\" or duodenojejunal loop) grows faster than the distal bowel (the \"postarterial\" or cecocolic loop), and",
"     </li>",
"     <li>",
"      The rapid growth of the liver.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The primary loop continues to grow, and then returns to the abdomen during the 8",
"    <sup>",
"     th",
"    </sup>",
"    to 10",
"    <sup>",
"     th",
"    </sup>",
"    week of gestation. With the return to the abdomen, there is an additional 180 degrees counterclockwise rotation. The overall effect is that the bowel rotates 270 degrees counterclockwise from the original primary loop (",
"    <a class=\"graphic graphic_figure graphicRef78643 \" href=\"UTD.htm?7/52/8007\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef68817 \" href=\"UTD.htm?12/60/13255\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Once the bowel has rotated into its final position, fixation to the posterior abdomen occurs. The proximal portion of the bowel is fixed to the retroperitoneum early in gestation (at the ligament of Treitz), whereas fixation of the colon is gradual and usually completed near term [",
"    <a class=\"abstract\" href=\"UTD.htm?19/48/20232/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Normal gut development",
"    </span>",
"   </p>",
"   <p>",
"    Normal rotation and fixation result in a wide-based mesentery that extends from the ligament of Treitz in the left upper quadrant to the ileocecal valve in the right lower quadrant (",
"    <a class=\"graphic graphic_figure graphicRef60995 \" href=\"UTD.htm?22/26/22944\">",
"     figure 3",
"    </a>",
"    ). Most anomalies of rotation result in an abnormally narrow mesenteric base (",
"    <a class=\"graphic graphic_figure graphicRef70398 \" href=\"UTD.htm?17/33/17936\">",
"     figure 4",
"    </a>",
"    ). Because the midgut is suspended on this narrow vascular pedicle rather than on the wide base of the mesentery, there is a risk of volvulus (torsion of the intestines).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Abnormal gut development",
"    </span>",
"   </p>",
"   <p>",
"    The most common abnormalities of rotation are nonrotation or malrotation abnormalities:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If both limbs of the primary loop return to the abdomen with no further rotation, nonrotation occurs. In this condition, the small bowel is located on the right of the abdomen and the colon on the left (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef77126 \" href=\"UTD.htm?18/59/19391\">",
"       image 1",
"      </a>",
"      ). Nonrotation is not as dangerous for the patient as malrotation because, in general, the base of the mesentery is wider than in malrotation, and the risk of volvulus is less. However, nonrotation is a difficult diagnosis radiologically, so these patients warrant laparoscopic or open exploration to confirm the diagnosis [",
"      <a class=\"abstract\" href=\"UTD.htm?19/48/20232/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In malrotation, the duodenojejunal limb remains in a position of nonrotation, and the cecocolic limb has partial rotation (usually approximately 90 degrees instead of 180 degrees). The end result is that the cecum ends up in the mid-upper abdomen and the abnormally positioned cecum is fixated to the right lateral abdominal wall by bands of peritoneum. These bands of peritoneum, called Ladd bands, cross the duodenum and can cause extrinsic compression and obstruction of the duodenum (",
"      <a class=\"graphic graphic_picture graphicRef82248 \" href=\"UTD.htm?19/17/19731\">",
"       picture 1",
"      </a>",
"      ) and (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef72551 \" href=\"UTD.htm?35/63/36848\">",
"       image 2",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other rare anomalies of rotation can occur [",
"    <a class=\"abstract\" href=\"UTD.htm?19/48/20232/abstract/1\">",
"     1",
"    </a>",
"    ]. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Reverse rotation of the duodenojejunal limb resulting in a duodenum that rests anterior to the superior mesenteric artery.",
"     </li>",
"     <li>",
"      Reverse rotation of the cecocolic limb resulting in a transverse colon that is posterior to the superior mesenteric artery.",
"     </li>",
"     <li>",
"      Reverse rotation of the duodenojejunal limb with normal rotation of the cecocolic limb resulting in a paraduodenal hernia. In this anomaly, the duodenum is located anterior to the superior mesenteric artery. Anterior to the duodenum, the cecocolic limb rotates normally, and the mesentery of the right colon creates a pouch into which the small bowel can herniate.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     General considerations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two anatomic features of malrotation lead to the clinical symptoms:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The narrow mesenteric base permits abnormal mobility of the small bowel, allowing the mesentery to twist (",
"      <a class=\"graphic graphic_figure graphicRef78111 \" href=\"UTD.htm?28/19/28977\">",
"       figure 5",
"      </a>",
"      ). The resulting volvulus causes small bowel ischemia.",
"     </li>",
"     <li>",
"      Ladd bands, which cross the duodenum, can lead to obstruction.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Most individuals with intestinal malrotation develop signs of acute small bowel obstruction in early infancy. Intestinal malrotation should be considered in any infant with bilious vomiting and any child with bilious emesis and abdominal pain.",
"   </p>",
"   <p>",
"    Physical examination may reveal mild distension of the abdomen, diffuse tenderness with or without signs of peritonitis, and bloody stool on rectal examination. Blood in the stool is a worrisome sign, since it suggests bowel ischemia and possible necrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/48/20232/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Volvulus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Over 50 percent of children with malrotation present before one month of age with the life-threatening complication of volvulus [",
"    <a class=\"abstract\" href=\"UTD.htm?19/48/20232/abstract/11\">",
"     11",
"    </a>",
"    ]. Volvulus occurs when small bowel twists around the superior mesenteric artery resulting in vascular compromise to large portions of the midgut (",
"    <a class=\"graphic graphic_figure graphicRef78111 \" href=\"UTD.htm?28/19/28977\">",
"     figure 5",
"    </a>",
"    ). This leads to ischemia and necrosis of the bowel that becomes irreversible, unless quickly corrected.",
"   </p>",
"   <p>",
"    Vomiting, which may or may not be bilious, occurs in &gt;90 percent of newborns with volvulus and is by far the most common presenting symptom of malrotation in infancy [",
"    <a class=\"abstract\" href=\"UTD.htm?19/48/20232/abstract/4\">",
"     4",
"    </a>",
"    ]. Third space fluid losses and sepsis, caused by necrotic bowel, can cause rapidly progressive cardiovascular compromise. Prompt fluid resuscitation and surgical intervention are essential.",
"   </p>",
"   <p>",
"    Approximately 22 percent of older children and 12 percent of adults with malrotation present with volvulus [",
"    <a class=\"abstract\" href=\"UTD.htm?19/48/20232/abstract/4\">",
"     4",
"    </a>",
"    ]. The onset of symptoms is usually acute, but some children and adults present with a more chronic pattern of episodic vomiting and abdominal pain suggestive of intermittent volvulus over the course of weeks to months to years [",
"    <a class=\"abstract\" href=\"UTD.htm?19/48/20232/abstract/4,14\">",
"     4,14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Duodenal obstruction",
"    </span>",
"    &nbsp;&mdash;&nbsp;In neonates, malrotation can also present as duodenal obstruction. The obstruction may be caused by Ladd bands (",
"    <a class=\"graphic graphic_figure graphicRef78111 \" href=\"UTD.htm?28/19/28977\">",
"     figure 5",
"    </a>",
"    ) or associated duodenal atresia. As many as 50 percent of patients with duodenal atresia have an associated malrotation [",
"    <a class=\"abstract\" href=\"UTD.htm?19/48/20232/abstract/9,10\">",
"     9,10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Other presentations",
"    </span>",
"    &nbsp;&mdash;&nbsp;In older children and adults, the clinical presentation of malrotation is variable and often insidious [",
"    <a class=\"abstract\" href=\"UTD.htm?19/48/20232/abstract/4,15-20\">",
"     4,15-20",
"    </a>",
"    ]. The most common symptom is abdominal pain [",
"    <a class=\"abstract\" href=\"UTD.htm?19/48/20232/abstract/4\">",
"     4",
"    </a>",
"    ]. Vomiting is also frequently present, but not necessarily, bilious; and both abdominal pain and vomiting may be intermittent [",
"    <a class=\"abstract\" href=\"UTD.htm?19/48/20232/abstract/4,11\">",
"     4,11",
"    </a>",
"    ]. Other, less common presentations include failure to thrive, solid food intolerance, malabsorption, chronic diarrhea from protein-losing enteropathy, pancreatitis, peritonitis, biliary obstruction, motility disorders, or chylous ascites [",
"    <a class=\"abstract\" href=\"UTD.htm?19/48/20232/abstract/7,11,21-25\">",
"     7,11,21-25",
"    </a>",
"    ]. Older children and adults with chronic symptoms may have been previously diagnosed with other chronic gastrointestinal disorders, such as allergy, irritable colon, functional abdominal pain, or cyclic vomiting [",
"    <a class=\"abstract\" href=\"UTD.htm?19/48/20232/abstract/16,26,27\">",
"     16,26,27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of intestinal malrotation depends upon the age of the patient and the cardinal signs and symptoms. It includes other causes of intestinal obstruction, vomiting, and acute abdomen [",
"    <a class=\"abstract\" href=\"UTD.htm?19/48/20232/abstract/7\">",
"     7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In young premature infants, the presentation of necrotizing enterocolitis (NEC) may be difficult to distinguish from malrotation. However, the majority of infants with NEC have characteristic radiograph features present on plain abdominal radiograph (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef78676 \" href=\"UTD.htm?15/9/15508\">",
"       image 3",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/39/41591?source=see_link&amp;anchor=H8#H8\">",
"       \"Clinical features and diagnosis of necrotizing enterocolitis in newborns\", section on 'Abdominal radiography'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In older infants, intussusception also frequently is associated with bilious vomiting, abdominal distension, blood in the stool, and nonspecific findings on abdominal plain films. Ultrasound of the abdomen will show the &ldquo;bull&rsquo;s eye&rdquo; or &ldquo;coiled spring&rdquo; lesions that indicate layers of intestine within intestine (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef68659 \" href=\"UTD.htm?21/16/21763\">",
"       image 4",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/20/35145?source=see_link&amp;anchor=H11#H11\">",
"       \"Intussusception in children\", section on 'Ultrasonography'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In children, adolescents, and adults, differential diagnostic considerations also include a variety of illnesses which can present with abdominal pain or vomiting. If a volvulus is present, the differential includes perforated viscus, appendicitis, or other causes of peritonitis. Differentiating among these various conditions is discussed in more detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/61/22490?source=see_link\">",
"       \"Emergent evaluation of the child with acute abdominal pain\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/60/24521?source=see_link\">",
"       \"Approach to the infant or child with nausea and vomiting\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/47/16120?source=see_link\">",
"       \"Approach to the adult with nausea and vomiting\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/36/19018?source=see_link\">",
"       \"Diagnostic approach to abdominal pain in adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of intestinal malrotation should be suspected in any infant who presents with bilious emesis, acute duodenal obstruction or abdominal tenderness associated with hemodynamic deterioration. In a case series of 52 infants under one year of age, vomiting was the presenting symptom in 93 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?19/48/20232/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In older children and adults, abdominal pain is the most common symptom and may present with abrupt onset over hours or days or as chronic intermittent pain over weeks, months, or years [",
"    <a class=\"abstract\" href=\"UTD.htm?19/48/20232/abstract/4\">",
"     4",
"    </a>",
"    ]. Intermittent vomiting, chronic diarrhea, malabsorption, or failure to thrive comprises other potential presenting symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?19/48/20232/abstract/1,4,24\">",
"     1,4,24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When malrotation is complicated by volvulus, it is a potentially life-threatening condition and requires emergent evaluation and treatment. If the child has volvulus with signs of systemic decompensation (eg, hematemesis, hematochezia, abdominal distension, peritonitis, and shock), no additional evaluation is needed. The child should be rapidly resuscitated and immediately taken to surgery for exploration. (see",
"    <a class=\"local\" href=\"#H17\">",
"     'Treatment'",
"    </a>",
"    below)",
"   </p>",
"   <p>",
"    If the child is hemodynamically stable, the diagnosis should be confirmed by radiologic evaluation. This evaluation typically begins with plain radiographs, which are rarely diagnostic but are important to exclude obvious perforation indicated by pneumoperitoneum. Plain radiographs are followed by an upper GI contrast series, which is the best examination to visualize the duodenum in infants and children. It should be performed, whenever possible, under fluoroscopy by an experienced pediatric radiologist.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"     Barium",
"    </a>",
"    enema and ultrasonography can be useful adjuncts when abnormal findings are present, but normal findings do not exclude malrotation. Computed tomography of the abdomen with intravenous contrast is not the recommended diagnostic study for malrotation in infants and children but may be appropriate in adults. Radiographic findings suggestive of malrotation are listed in the table (",
"    <a class=\"graphic graphic_table graphicRef60568 \" href=\"UTD.htm?18/40/19084\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Plain radiographs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plain radiographs are rarely helpful in the diagnosis of malrotation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    volvulus. In patients with volvulus, the plain radiograph typically shows a gasless abdomen, but may show only mild intestinal dilatation, or may be completely normal (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef52558 \" href=\"UTD.htm?11/63/12273\">",
"     image 5",
"    </a>",
"    ). Findings that are diagnostic on plain film include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A nasogastric or orogastric tube that extends into an abnormally positioned duodenum.",
"     </li>",
"     <li>",
"      The \"double-bubble\" sign, signifying duodenal obstruction (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef73385 \" href=\"UTD.htm?4/61/5087\">",
"       image 6",
"      </a>",
"      ); partial obstruction of the duodenum causes distension of the stomach and first part of the duodenum.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Upper GI series",
"    </span>",
"    &nbsp;&mdash;&nbsp;A limited upper gastrointestinal (GI) contrast series is the best examination to visualize the duodenum. It should be performed, whenever possible, under fluoroscopy and by an experienced pediatric radiologist. In approximately 25 percent of cases, the upper GI findings are subtle, and the radiographic diagnosis may be difficult [",
"    <a class=\"abstract\" href=\"UTD.htm?19/48/20232/abstract/28-30\">",
"     28-30",
"    </a>",
"    ]. However, in the remaining 75 percent of cases, the signs of malrotation are obvious. These findings include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A clearly misplaced duodenum (ie, ligament of Treitz on the right side of the abdomen) that has a \"corkscrew\" appearance (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef75419 \" href=\"UTD.htm?29/1/29713\">",
"       image 7",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Duodenal obstruction, which may appear similar to that seen with duodenal atresia (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef64334 \" href=\"UTD.htm?29/38/30318\">",
"       image 8",
"      </a>",
"      ), or may have more of a \"beak\" appearance if a volvulus is present.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The false-negative and -positive rates of upper GI series in the diagnosis of malrotation are 6 to 14 percent and 7 to 15 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?19/48/20232/abstract/2\">",
"     2",
"    </a>",
"    ]. When the limited upper GI series is equivocal and there is a high index of suspicion or signs of distal bowel obstruction, it may be helpful to add small bowel follow-through, repeat the study when the patient is symptomatic [",
"    <a class=\"abstract\" href=\"UTD.htm?19/48/20232/abstract/31\">",
"     31",
"    </a>",
"    ], or evaluate colonic rotation with a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    enema [",
"    <a class=\"abstract\" href=\"UTD.htm?19/48/20232/abstract/28,29\">",
"     28,29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Barium enema",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"     Barium",
"    </a>",
"    enema may be misleading in the diagnosis of malrotation, and is used only as an adjunct to the upper GI series. Because the final fixation of the colon does not occur until near term, many newborns have a high or poorly-fixed cecum, which can mimic malrotation and result in a false-positive study. Conversely, in approximately 20 percent of cases of malrotation, the cecum is normally located in the right lower quadrant (false-negative) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/48/20232/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. Barium enema can be helpful in the diagnosis of volvulus if it shows complete obstruction of the transverse colon, particularly if the head of the barium column has a beaked appearance (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef72551 \" href=\"UTD.htm?35/63/36848\">",
"     image 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/48/20232/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Ultrasonography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ultrasonography (US) can be used to diagnose or screen for malrotation. Ultrasonographic findings that are suggestive of malrotation include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Third part of the duodenum is not in the normal retromesenteric position (ie, located between the mesenteric artery and the aorta in the retroperitoneal space) [",
"      <a class=\"abstract\" href=\"UTD.htm?19/48/20232/abstract/35\">",
"       35",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Abnormal position of the superior mesenteric vein (either anterior or to the left of the superior mesenteric artery [SMA]) [",
"      <a class=\"abstract\" href=\"UTD.htm?19/48/20232/abstract/36,37\">",
"       36,37",
"      </a>",
"      ]; the superior mesenteric vein is normally located to the right of the SMA",
"     </li>",
"     <li>",
"      The \"whirlpool\" sign of volvulus (caused by the vessels twisting around the base of the mesenteric pedicle) [",
"      <a class=\"abstract\" href=\"UTD.htm?19/48/20232/abstract/37,38\">",
"       37,38",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Dilated duodenum (indicating duodenal obstruction by Ladd bands) [",
"      <a class=\"abstract\" href=\"UTD.htm?19/48/20232/abstract/38\">",
"       38",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A normal ultrasonogram does not exclude malrotation [",
"    <a class=\"abstract\" href=\"UTD.htm?19/48/20232/abstract/39\">",
"     39",
"    </a>",
"    ]. This has been demonstrated in two large retrospective series in which 2 and 3 percent of children with normal US evaluations had malrotation diagnosed with upper GI series [",
"    <a class=\"abstract\" href=\"UTD.htm?19/48/20232/abstract/37,40\">",
"     37,40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Given the grave consequences of missing the diagnosis, upper GI series remains the gold standard for diagnosing malrotation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15451346\">",
"    <span class=\"h2\">",
"     Computed tomography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Computed tomography (CT) of the abdomen should not be the initial diagnostic test for malrotation in infants, children, and adolescents because of the potential radiation exposure when compared to an upper gastrointestinal (GI) contrast series. However, in adults, abdominal CT is favored by some experts because in addition to findings that indicate malrotation (eg, the third part of the duodenum does not pass between the superior mesenteric artery and the aorta), it also provides information concerning bowel location and perfusion, and the presence of volvulus. Furthermore, it is the preferred test for a variety of other causes of surgical abdominal pain in adults. As an example, in a case series of 82 adults diagnosed with malrotation, imaging consisted of CT scan in 61 percent and upper GI series in 27 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?19/48/20232/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Findings consistent with malrotation on abdominal CT with intravenous contrast include [",
"    <a class=\"abstract\" href=\"UTD.htm?19/48/20232/abstract/41\">",
"     41",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The third part of the duodenum does not pass between the mesenteric artery and the aorta.",
"     </li>",
"     <li>",
"      The proximal small bowel is mostly located to the right of the midline.",
"     </li>",
"     <li>",
"      There is an abnormal position of the superior mesenteric vein and superior mesenteric artery.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8142910\">",
"    <span class=\"h2\">",
"     Laparoscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laparoscopy is a less invasive option than laparotomy for determining the presence of volvulus in children for whom diagnostic imaging is equivocal or suggests malrotation without volvulus. For example, in a case series of children with a median age of 18 months (range four days to 16 years) who were undergoing evaluation for malrotation, 13 of 24 patients with a preoperative diagnosis of malrotation without volvulus had volvulus on laparoscopy, 3 of these 24 patients had normal rotation, and 6 of 19 patients with equivocal imaging findings had malrotation discovered by laparoscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?19/48/20232/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Malrotation is treated surgically with the Ladd procedure. The purpose of the Ladd procedure is not to return the bowel to a normal configuration, which is anatomically impossible, but rather to minimize future risk of volvulus by widening the base of the mesentery, and placing the bowel in a position of nonrotation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Symptomatic malrotation",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients with volvulus or suspected volvulus and systemic decompensation should proceed directly to laparotomy. Preoperative management includes cardiopulmonary and circulatory resuscitation, the placement of a gastric decompression tube, and the administration of broad-spectrum antibiotics to cover gut flora.",
"   </p>",
"   <p>",
"    At the time of surgical exploration, if a volvulus is present, it is untwisted in a counterclockwise fashion. In addition, the Ladd procedure for correction of malrotation consists of:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Division of the Ladd bands, if present",
"     </li>",
"     <li>",
"      Widening of the base of the mesentery by dividing any adhesions between the duodenum and cecum at the base of the mesentery",
"     </li>",
"     <li>",
"      Passing a tube through the duodenum to rule out any associated duodenal obstruction (in the newborn)",
"     </li>",
"     <li>",
"      Appendectomy",
"     </li>",
"     <li>",
"      Placing viable bowel in a position of nonrotation (ie, small bowel on the right and colon on the left). If the viability of the bowel is in question, the abdomen can be closed and the bowel reevaluated after 24 to 36 hours. If frankly necrotic bowel is present, it is resected and stomas are created.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Laparoscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Ladd procedure for malrotation can be performed laparoscopically in the absence of volvulus or bowel ischemia, particularly in the older child or adult [",
"    <a class=\"abstract\" href=\"UTD.htm?19/48/20232/abstract/4,43-46\">",
"     4,43-46",
"    </a>",
"    ]. It has been suggested that the laparoscopic approach may be associated with a higher recurrence rate, because of fewer adhesions after surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?19/48/20232/abstract/21\">",
"     21",
"    </a>",
"    ]. However, there have been no prospective studies to compare laparoscopic and open correction of malrotation. In most institutions, the open procedure is the standard procedure, with only a limited number of patients undergoing laparoscopic procedures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Asymptomatic malrotation",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is some controversy in the literature about the treatment of the \"asymptomatic\" malrotation. Perhaps this condition is more aptly called \"incidentally detected\" malrotation, since upper gastrointestinal contrast studies are rarely performed in patients without symptoms.",
"   </p>",
"   <p>",
"    Although most patients with volvulus present in the newborn period, it is not clear that the risk of volvulus decreases with age [",
"    <a class=\"abstract\" href=\"UTD.htm?19/48/20232/abstract/2,4,11,19,21\">",
"     2,4,11,19,21",
"    </a>",
"    ]. It is also difficult, if not impossible, to determine with imaging studies whether a patient with a rotational anomaly has a narrow-based mesentery, which increases the risk of volvulus. For this reason, most surgeons recommend surgery when malrotation is diagnosed, regardless of the patient's age or the presence of symptoms characteristic of malrotation [",
"    <a class=\"abstract\" href=\"UTD.htm?19/48/20232/abstract/4,19,21,23\">",
"     4,19,21,23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The use of laparoscopy to assess the mobility of the colon and the width of the mesentery has been advocated by some surgeons for asymptomatic patients [",
"    <a class=\"abstract\" href=\"UTD.htm?19/48/20232/abstract/21,44,45\">",
"     21,44,45",
"    </a>",
"    ]. In patients with narrow mesenteric attachment and potential colonic mobility, definitive laparoscopic correction can then be undertaken.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complications of the Ladd procedure are unusual in the absence of compromised bowel from volvulus. Patients with a volvulus may have short gut syndrome if bowel resection is required and are at risk for small bowel obstruction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Short gut syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Resection of the entire small bowel and ascending colon may be necessary in patients with malrotation and midgut volvulus if necrotic bowel is present at the time of surgery. In one series of 68 consecutive children who had a Ladd procedure for malrotation, midgut volvulus was present in 40, and among these, gangrenous bowel was present in three (7.5 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/48/20232/abstract/47\">",
"     47",
"    </a>",
"    ]. Of these, one died, and two had short gut syndrome. This complication is only preventable through prompt recognition and management of malrotation and midgut volvulus [",
"    <a class=\"abstract\" href=\"UTD.htm?19/48/20232/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Small bowel obstruction",
"    </span>",
"    &nbsp;&mdash;&nbsp;After any laparotomy, patients are at risk for small bowel obstruction from adhesions. This is unusual, but has been reported in as many as 15 percent of patients in some series [",
"    <a class=\"abstract\" href=\"UTD.htm?19/48/20232/abstract/2,20\">",
"     2,20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     OUTCOMES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15451562\">",
"    <span class=\"h2\">",
"     Resolution of symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Resolution of symptoms occurs in up to 89 percent of patients who undergo operative intervention [",
"    <a class=\"abstract\" href=\"UTD.htm?19/48/20232/abstract/4\">",
"     4",
"    </a>",
"    ]. Persistent symptoms postoperatively are less common in infants, children under 18 years of age, and patients with malrotation and volvulus. In contrast, only 4 of 12 symptomatic patients who did not receive operative intervention had resolution of symptoms in one observational study [",
"    <a class=\"abstract\" href=\"UTD.htm?19/48/20232/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Mortality",
"    </span>",
"    &nbsp;&mdash;&nbsp;The overall mortality rate after surgery for malrotation is 3 to 9 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?19/48/20232/abstract/18,48,49\">",
"     18,48,49",
"    </a>",
"    ]. Mortality is increased in patients with volvulus, intestinal necrosis, prematurity, and associated anomalies [",
"    <a class=\"abstract\" href=\"UTD.htm?19/48/20232/abstract/18,48\">",
"     18,48",
"    </a>",
"    ], and approaches zero in otherwise healthy children without intestinal ischemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Recurrent volvulus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgery for malrotation reduces the risk of recurrent volvulus by widening the base of the mesentery (and presumably causing some adhesions). The risk is not eliminated because the underlying embryologic defect cannot be corrected. The risk of recurrence has been estimated to be between 1.8 and 8.0 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?19/48/20232/abstract/2,11\">",
"     2,11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rotational anomalies occur as a result of an arrest of normal rotation of the embryonic gut. They are often associated with other gastrointestinal abnormalities, but can also occur in otherwise healthy children and adults. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Pathogenesis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Vomiting, which may or may not be bilious, occurs in &gt;90 percent of newborns with volvulus and is by far the most common presenting symptom of malrotation in infancy and is often accompanied by abdominal distension and tenderness. Hematochezia is a worrisome sign of bowel ischemia. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Volvulus'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'General considerations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The presentation of intestinal malrotation in older children and adults is variable and often insidious. They too may present with midgut volvulus, but more often have intermittent vomiting or abdominal pain. Less common presentations include failure to thrive, solid food intolerance, malabsorption, chronic diarrhea, pancreatitis, peritonitis, biliary obstruction, motility disorders, or chylous ascites. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Malrotation with volvulus can be a life-threatening condition that requires emergent evaluation and treatment. If signs of systemic decompensation are present, the patient should be rapidly resuscitated and proceed immediately to surgery.",
"     </li>",
"     <li>",
"      For the child who is stable, radiologic evaluation may be undertaken. An upper GI contrast series is the best initial examination to visualize the duodenum in children.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"       Barium",
"      </a>",
"      enema and ultrasonography can be useful adjuncts, but normal findings do not exclude malrotation. Radiographic findings suggestive of malrotation are listed in the table (",
"      <a class=\"graphic graphic_table graphicRef60568 \" href=\"UTD.htm?18/40/19084\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Malrotation, regardless of the age of the patient and the presence of symptoms, is treated surgically with a Ladd procedure. This procedure begins with reduction of the volvulus, if present. Since the appendix ends up in the left mid- to upper abdomen, an appendectomy is performed as well. If, after surgical reduction of a volvulus, the viability of the bowel is in question, the abdomen can be closed and the bowel reevaluated after 24 to 36 hours. If frankly necrotic bowel is present, it is resected and stomas are created. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The Ladd procedure for malrotation can be performed laparoscopically in the absence of volvulus or bowel ischemia, particularly in the older child or adult. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Laparoscopy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Warner B. Malrotation. In: Surgery of Infants and Children: Scientific Principles and Practice, Oldham KT, Colombani PM, Foglia RP (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 1997. p.1229.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20232/abstract/2\">",
"      Dilley AV, Pereira J, Shi EC, et al. The radiologist says malrotation: does the surgeon operate? Pediatr Surg Int 2000; 16:45.",
"     </a>",
"    </li>",
"    <li>",
"     Berseth CL. Disorders of the intestines and pancreas. In: Avery's Diseases of the Newborn, 7th, Taeusch WH, Ballard RA (Eds), WB Saunders, Philadelphia 1998. p.918.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20232/abstract/4\">",
"      Nehra D, Goldstein AM. Intestinal malrotation: varied clinical presentation from infancy through adulthood. Surgery 2011; 149:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20232/abstract/5\">",
"      Stewart DR, Colodny AL, Daggett WC. Malrotation of the bowel in infants and children: a 15 year review. Surgery 1976; 79:716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20232/abstract/6\">",
"      Filston HC, Kirks DR. Malrotation - the ubiquitous anomaly. J Pediatr Surg 1981; 16:614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20232/abstract/7\">",
"      KIESEWETTER WB, SMITH JW. Malrotation of the midgut in infancy and childhood. AMA Arch Surg 1958; 77:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20232/abstract/8\">",
"      Ford EG, Senac MO Jr, Srikanth MS, Weitzman JJ. Malrotation of the intestine in children. Ann Surg 1992; 215:172.",
"     </a>",
"    </li>",
"    <li>",
"     Smith EI. Malrotation of the intestine. In: Pediatric Surgery, 4th, Welch KJ, Randolph JG, Ravich MR, et al (Eds), Year Book Medical, Chicago 1986. p.882.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20232/abstract/10\">",
"      GLOVER DM, BARRY FM. Intestinal obstruction in the newborn. Ann Surg 1949; 130:480.",
"     </a>",
"    </li>",
"    <li>",
"     Fonkalsrud E. Rotational anomalies and volvulus. In: Principles of Pediatric Surgery, O'Neill JA et al (Ed), Mosby, St. Louis 2003. p.477.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20232/abstract/12\">",
"      Diaz, MCG, Reichard, K, Taylor, AA. Intestinal nonrotation in an adolescent. Pediatr Emer Care 2009; 25: 249.",
"     </a>",
"    </li>",
"    <li>",
"     Bachur RG. Abdominal emergencies. In: Textbook of Pediatric Emergency Medicine, 5th, Fleisher GR, Ludwig S, Henretig FM (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. p.1605.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20232/abstract/14\">",
"      Millar AJ, Rode H, Cywes S. Malrotation and volvulus in infancy and childhood. Semin Pediatr Surg 2003; 12:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20232/abstract/15\">",
"      von Fl&uuml;e M, Herzog U, Ackermann C, et al. Acute and chronic presentation of intestinal nonrotation in adults. Dis Colon Rectum 1994; 37:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20232/abstract/16\">",
"      WANG CA, WELCH CE. ANOMALIES OF INTESTINAL ROTATION IN ADOLESCENTS AND ADULTS. Surgery 1963; 54:839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20232/abstract/17\">",
"      Pickhardt PJ, Bhalla S. Intestinal malrotation in adolescents and adults: spectrum of clinical and imaging features. AJR Am J Roentgenol 2002; 179:1429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20232/abstract/18\">",
"      Rescorla FJ, Shedd FJ, Grosfeld JL, et al. Anomalies of intestinal rotation in childhood: analysis of 447 cases. Surgery 1990; 108:710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20232/abstract/19\">",
"      Powell DM, Othersen HB, Smith CD. Malrotation of the intestines in children: the effect of age on presentation and therapy. J Pediatr Surg 1989; 24:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20232/abstract/20\">",
"      Lin JN, Lou CC, Wang KL. Intestinal malrotation and midgut volvulus: a 15-year review. J Formos Med Assoc 1995; 94:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20232/abstract/21\">",
"      Prasil P, Flageole H, Shaw KS, et al. Should malrotation in children be treated differently according to age? J Pediatr Surg 2000; 35:756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20232/abstract/22\">",
"      Kirby CP, Freeman JK, Ford WD, et al. Malrotation with recurrent volvulus presenting with cholestasis, pruritus, and pancreatitis. Pediatr Surg Int 2000; 16:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20232/abstract/23\">",
"      Spigland N, Brandt ML, Yazbeck S. Malrotation presenting beyond the neonatal period. J Pediatr Surg 1990; 25:1139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20232/abstract/24\">",
"      Brandt ML, Pokorny WJ, McGill CW, Harberg FJ. Late presentations of midgut malrotation in children. Am J Surg 1985; 150:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20232/abstract/25\">",
"      Yanez R, Spitz L. Intestinal malrotation presenting outside the neonatal period. Arch Dis Child 1986; 61:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20232/abstract/26\">",
"      Kullendorff CM, Mikaelsson C, Ivancev K. Malrotation in children with symptoms of gastrointestinal allergy and psychosomatic abdominal pain. Acta Paediatr Scand 1985; 74:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20232/abstract/27\">",
"      Gardner, CE. Hart, D. Anomalies of intestinal rotation as a cause of intestinal obstructions: report of two personal observations: review of one hundred and three reported cases. Arch Surg 1934; 29:942.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20232/abstract/28\">",
"      Long FR, Kramer SS, Markowitz RI, et al. Intestinal malrotation in children: tutorial on radiographic diagnosis in difficult cases. Radiology 1996; 198:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20232/abstract/29\">",
"      Long FR, Kramer SS, Markowitz RI, Taylor GE. Radiographic patterns of intestinal malrotation in children. Radiographics 1996; 16:547.",
"     </a>",
"    </li>",
"    <li>",
"     American College of Radiology. ACR appropriateness criteria. Vomiting in infants up to 3 months of age. Available at file://www.acr.org/~/media/ACR/Documents/AppCriteria/Diagnostic/VomitingInInfantsUpTo3MonthsOfAge.pdf. Accessed August 6, 2012.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20232/abstract/31\">",
"      Berdon WE. The diagnosis of malrotation and volvulus in the older child and adult: a trap for radiologists. Pediatr Radiol 1995; 25:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20232/abstract/32\">",
"      Morrison SC. Controversies in abdominal imaging. Pediatr Clin North Am 1997; 44:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20232/abstract/33\">",
"      Firor HV, Harris VJ. Rotational abnormalities of the gut. Re-emphasis of a neglected facet, isolated incomplete rotation of the duodenum. Am J Roentgenol Radium Ther Nucl Med 1974; 120:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20232/abstract/34\">",
"      Siegel MJ, Shackelford GD, McAlister WH. Small bowel volvulus in children: its appearance on the barium enema examination. Pediatr Radiol 1980; 10:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20232/abstract/35\">",
"      Yousefzadeh DK. The position of the duodenojejunal junction: the wrong horse to bet on in diagnosing or excluding malrotation. Pediatr Radiol 2009; 39 Suppl 2:S172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20232/abstract/36\">",
"      Zerin JM, DiPietro MA. Superior mesenteric vascular anatomy at US in patients with surgically proved malrotation of the midgut. Radiology 1992; 183:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20232/abstract/37\">",
"      Dufour D, Delaet MH, Dassonville M, et al. Midgut malrotation, the reliability of sonographic diagnosis. Pediatr Radiol 1992; 22:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20232/abstract/38\">",
"      Pracros JP, Sann L, Genin G, et al. Ultrasound diagnosis of midgut volvulus: the \"whirlpool\" sign. Pediatr Radiol 1992; 22:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20232/abstract/39\">",
"      Ashley LM, Allen S, Teele RL. A normal sonogram does not exclude malrotation. Pediatr Radiol 2001; 31:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20232/abstract/40\">",
"      Orzech N, Navarro OM, Langer JC. Is ultrasonography a good screening test for intestinal malrotation? J Pediatr Surg 2006; 41:1005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20232/abstract/41\">",
"      Taylor GA. CT appearance of the duodenum and mesenteric vessels in children with normal and abnormal bowel rotation. Pediatr Radiol 2011; 41:1378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20232/abstract/42\">",
"      Hsiao M, Langer JC. Value of laparoscopy in children with a suspected rotation abnormality on imaging. J Pediatr Surg 2011; 46:1347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20232/abstract/43\">",
"      Bass KD, Rothenberg SS, Chang JH. Laparoscopic Ladd's procedure in infants with malrotation. J Pediatr Surg 1998; 33:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20232/abstract/44\">",
"      Waldhausen JH, Sawin RS. Laparoscopic Ladd's procedure and assessment of malrotation. J Laparoendosc Surg 1996; 6 Suppl 1:S103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20232/abstract/45\">",
"      Mazziotti MV, Strasberg SM, Langer JC. Intestinal rotation abnormalities without volvulus: the role of laparoscopy. J Am Coll Surg 1997; 185:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20232/abstract/46\">",
"      Lessin MS, Luks FI. Laparoscopic appendectomy and duodenocolonic dissociation (LADD) procedure for malrotation. Pediatr Surg Int 1998; 13:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20232/abstract/47\">",
"      Seashore JH, Touloukian RJ. Midgut volvulus. An ever-present threat. Arch Pediatr Adolesc Med 1994; 148:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20232/abstract/48\">",
"      Messineo A, MacMillan JH, Palder SB, Filler RM. Clinical factors affecting mortality in children with malrotation of the intestine. J Pediatr Surg 1992; 27:1343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20232/abstract/49\">",
"      Andrassy RJ, Mahour GH. Malrotation of the midgut in infants and children: a 25-year review. Arch Surg 1981; 116:158.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6477 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-110.170.48.130-B1CD8C1B47-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_48_20232=[""].join("\n");
var outline_f19_48_20232=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H27\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Normal gut development",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Abnormal gut development",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      General considerations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Volvulus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Duodenal obstruction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Other presentations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Plain radiographs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Upper GI series",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Barium enema",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Ultrasonography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15451346\">",
"      Computed tomography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8142910\">",
"      Laparoscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Symptomatic malrotation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Laparoscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Asymptomatic malrotation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Complications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Short gut syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Small bowel obstruction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      OUTCOMES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15451562\">",
"      Resolution of symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Mortality",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Recurrent volvulus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/6477\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6477|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?18/59/19391\" title=\"diagnostic image 1\">",
"      UGI duodenal bulb",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?35/63/36848\" title=\"diagnostic image 2\">",
"      Medial directed cecum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?15/9/15508\" title=\"diagnostic image 3\">",
"      Plain radiographs - necrotizing enterocolitis in preterm infants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?21/16/21763\" title=\"diagnostic image 4\">",
"      Intussusception Ultrasound",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?11/63/12273\" title=\"diagnostic image 5\">",
"      Ileus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?4/61/5087\" title=\"diagnostic image 6\">",
"      Plain radiograph of an infant with duodenal atresia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?29/1/29713\" title=\"diagnostic image 7\">",
"      Volvulus corkscrew",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?29/38/30318\" title=\"diagnostic image 8\">",
"      Contrast study in duodenal atresia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6477|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?7/52/8007\" title=\"figure 1\">",
"      Duodenojejunal rotation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?12/60/13255\" title=\"figure 2\">",
"      Cecocolic rotation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?22/26/22944\" title=\"figure 3\">",
"      Normal mesenteric fixation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?17/33/17936\" title=\"figure 4\">",
"      Fixation in malrotation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/19/28977\" title=\"figure 5\">",
"      Midgut volvulus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6477|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?19/17/19731\" title=\"picture 1\">",
"      Malrotation at surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6477|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/22/16747\" title=\"table 1\">",
"      Anomalies with malrotation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?18/40/19084\" title=\"table 2\">",
"      Radiographic signs malrotation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/47/16120?source=related_link\">",
"      Approach to the adult with nausea and vomiting",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/60/24521?source=related_link\">",
"      Approach to the infant or child with nausea and vomiting",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/39/41591?source=related_link\">",
"      Clinical features and diagnosis of necrotizing enterocolitis in newborns",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/36/19018?source=related_link\">",
"      Diagnostic approach to abdominal pain in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/61/22490?source=related_link\">",
"      Emergent evaluation of the child with acute abdominal pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/55/31608?source=related_link\">",
"      Intestinal atresia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/20/35145?source=related_link\">",
"      Intussusception in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/35/38454?source=related_link\">",
"      Obstetrical management of omphalocele",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/15/41205?source=related_link\">",
"      Overview of the development of the gastrointestinal tract",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_48_20233="Pathogenesis of IgA nephropathy";
var content_f19_48_20233=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pathogenesis of IgA nephropathy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/48/20233/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/48/20233/contributors\">",
"     Jonathan Barratt, PhD, FRCP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/48/20233/contributors\">",
"     John Feehally, DM, FRCP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/48/20233/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/48/20233/contributors\">",
"     Richard J Glassock, MD, MACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/48/20233/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/48/20233/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?19/48/20233/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 11, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;IgA nephropathy is the most common lesion found to cause primary glomerulonephritis throughout most developed countries of the world [",
"    <a class=\"abstract\" href=\"UTD.htm?19/48/20233/abstract/1-7\">",
"     1-7",
"    </a>",
"    ]. IgA deposits may also be seen on kidney biopsy in individuals with no evidence of renal disease [",
"    <a class=\"abstract\" href=\"UTD.htm?19/48/20233/abstract/8\">",
"     8",
"    </a>",
"    ]. The reported incidence of mesangial IgA deposition in apparently healthy individuals ranges from 3 to 16 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?19/48/20233/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. These cases had no clinical features of nephritis but their renal biopsy was consistent with IgA nephropathy.",
"   </p>",
"   <p>",
"    This observation raises three important points:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There is a large cohort of undiagnosed \"latent\" IgA nephropathy in the general population.",
"     </li>",
"     <li>",
"      This must be taken into account when genetic studies are undertaken comparing gene polymorphisms in IgAN with normal \"healthy\" populations.",
"     </li>",
"     <li>",
"      It raises an important consideration for the pathogenesis of IgA nephropathy: the process of mesangial IgA deposition is likely to be separate from the induction of glomerular injury and IgA deposition does not necessarily need to be followed by nephritis. Identifying the factors common to both processes is essential to our overall understanding of the pathogenesis of IgAN.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are also a number of reports documenting IgA deposition in other forms of glomerulonephritis. These particularly include thin basement membrane nephropathy, lupus nephritis, minimal change disease, and diabetic nephropathy. These findings are most probably due to chance associations, since IgA deposition is common in the general population.",
"   </p>",
"   <p>",
"    The pathogenesis and etiology of IgA nephropathy will be reviewed here. The clinical presentation and diagnosis and the treatment and prognosis of this disorder are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/19/1337?source=see_link\">",
"     \"Clinical presentation and diagnosis of IgA nephropathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/7/42106?source=see_link\">",
"     \"Treatment and prognosis of IgA nephropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MECHANISM OF INJURY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initiating event in the pathogenesis of IgA nephropathy is the mesangial deposition of IgA, which is predominantly polymeric IgA of the IgA1 subclass (polymeric IgA1-containing J chain). Codeposits of IgG and complement (C3 but usually not C1q) are also commonly seen and may contribute to disease severity. Mesangial deposition of secretory IgA has also been reported, but the pathogenic significance of this is unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?19/48/20233/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are",
"    <strong>",
"     four",
"    </strong>",
"    key elements that contribute to IgA nephropathy, and the extent to which each is operational determines the severity, course, and eventual outcome of IgA nephropathy in any individual [",
"    <a class=\"abstract\" href=\"UTD.htm?19/48/20233/abstract/11\">",
"     11",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Generation of circulating IgA immune complexes with chemical and biological characteristics that favor mesangial deposition.",
"     </li>",
"     <li>",
"      The ability of the reticuloendothelial system to effectively remove potentially pathogenic IgA immune complexes or under-glycosylated IgA",
"      <sub>",
"       1",
"      </sub>",
"      aggregates from the circulation.",
"     </li>",
"     <li>",
"      The mesangial cell affinity for and reaction to mesangial under-glycosylated IgA1 accumulation.",
"     </li>",
"     <li>",
"      The inherent tendency of the kidney to respond to injury by mounting a response favoring progressive renal injury with glomerulosclerosis and interstitial fibrosis, rather than resolution of inflammation without these sequelae.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The mechanisms of secondary renal injury are probably similar to those underlying other forms of chronic kidney disease and are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/19/26938?source=see_link\">",
"     \"Secondary factors and progression of chronic kidney disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/6/41066?source=see_link&amp;anchor=H13#H13\">",
"     \"Epidemiology, classification, and pathogenesis of focal segmental glomerulosclerosis\", section on 'Secondary FSGS'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Characteristics of pathogenic IgA",
"    </span>",
"    &nbsp;&mdash;&nbsp;An increased plasma IgA level alone is not sufficient to produce mesangial IgA deposits. Thus, patients with IgA nephropathy must produce a pool of circulating IgA molecules with special characteristics that promote mesangial deposition.",
"   </p>",
"   <p>",
"    The heterogeneity in reported abnormalities suggests that there is more than one mechanism leading to the production of pathogenic circulating IgA immune complexes [",
"    <a class=\"abstract\" href=\"UTD.htm?19/48/20233/abstract/12\">",
"     12",
"    </a>",
"    ]. The following are some of the described abnormalities in circulating IgA and its production in IgA nephropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?19/48/20233/abstract/12-15\">",
"     12-15",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The serum IgA is anionic and lambda light chains are over-represented.",
"     </li>",
"     <li>",
"      There is an increase in the amount of polymeric IgA in the serum.",
"     </li>",
"     <li>",
"      There is a high proportion of poorly O-galactosylated IgA1. (See",
"      <a class=\"local\" href=\"#H22581665\">",
"       'Poor O-galactosylation of IgA1'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      There are alterations in IgA1 sialylation. (See",
"      <a class=\"local\" href=\"#H22581672\">",
"       'Alterations of IgA1 sialylation'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22581665\">",
"    <span class=\"h3\">",
"     Poor O-galactosylation of IgA1",
"    </span>",
"    &nbsp;&mdash;&nbsp;Compared with healthy subjects without IgA nephropathy, there is an increase in the proportion of poorly galactosylated IgA1 O-glycoforms in the serum (the IgA1 hinge region is variably glycosylated in health resulting in an array of different IgA1 glycoforms appearing in the serum). This increase in poorly galactosylated IgA1 O-glycoforms is found in serum IgA, as well as in IgA1 eluted from isolated renal tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?19/48/20233/abstract/13,14,16\">",
"     13,14,16",
"    </a>",
"    ]. Similar findings have been reported in children with either IgA nephropathy or Henoch-Sch&ouml;nlein purpura (IgA vasculitis) nephritis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/48/20233/abstract/17\">",
"     17",
"    </a>",
"    ]. However, patients with IgA nephropathy can produce IgD that is highly galactosylated [",
"    <a class=\"abstract\" href=\"UTD.htm?19/48/20233/abstract/15\">",
"     15",
"    </a>",
"    ]. In addition, only a small fraction of serum IgA1 is poorly galactosylated, and only a small proportion of IgA1-committed plasma cells are synthesizing these poorly O-galactosylated glycoforms of IgA1. It is therefore unlikely that there is an overarching &ldquo;defect&rdquo; in immunoglobulin O-glycosylation in IgAN.",
"   </p>",
"   <p>",
"    Poorly galactosylated IgA1 O-glycoforms have an increased tendency to both self-aggregate and form antigen-antibody complexes with IgG antibodies directed against an N-acetylgalactosamine residue in the IgA1 hinge region [",
"    <a class=\"abstract\" href=\"UTD.htm?19/48/20233/abstract/18-20\">",
"     18-20",
"    </a>",
"    ]. Both mechanisms favor the generation of macromolecular aggregates of polymeric IgA1 and IgA-immune complexes, which are more likely to deposit in the mesangium [",
"    <a class=\"abstract\" href=\"UTD.htm?19/48/20233/abstract/21,22\">",
"     21,22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    IgA1 molecules lacking terminal galactose units have increased in vitro affinity for the extracellular matrix components fibronectin and type IV collagen [",
"    <a class=\"abstract\" href=\"UTD.htm?19/48/20233/abstract/22\">",
"     22",
"    </a>",
"    ], which will promote mesangial deposition.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22581759\">",
"    <span class=\"h4\">",
"     Causes of poor O-galactosylation",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is evidence to suggest that an individual&rsquo;s serum IgA1 O-glycoform profile is an inherited, rather than acquired, trait [",
"    <a class=\"abstract\" href=\"UTD.htm?19/48/20233/abstract/23\">",
"     23",
"    </a>",
"    ]. Segregation analysis suggests the presence of a major dominant gene on a polygenic background.",
"   </p>",
"   <p>",
"    As an example, a polymorphism in core 1 b1,3-galactosyltransferase 1 (C1Gal-T1), which is one of the enzymes responsible for O-galactosylation of IgA1, is associated with IgA nephropathy in some populations. Mutations in Cosmc, the C1GAL-T1 chaperone protein, are also associated with disease in some studies. However, there is no evidence in three genome wide association studies (GWAS) in Europeans and Asians that IgAN is associated with susceptibility loci associated with O-glycosylation enzymes [",
"    <a class=\"abstract\" href=\"UTD.htm?19/48/20233/abstract/24-26\">",
"     24-26",
"    </a>",
"    ].(See",
"    <a class=\"local\" href=\"#H15\">",
"     'Genetic predisposition'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In addition, the expression of C1GAL-T1, and therefore the O-galactosylation of IgA1, are regulated by microRNA (miRNA). MicroRNAs are endogenous small (18 to 24 nucleotides long) noncoding single-stranded RNAs that regulate gene expression at the posttranscriptional level. Specifically, miRNAs bind to the messenger RNAs of various genes and lead to their degradation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/47/39674?source=see_link&amp;anchor=H5280328#H5280328\">",
"     \"Overview of gene expression profiling, proteomics, and microRNA profiling in clinical oncology\", section on 'MicroRNA profiling'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a study that examined the miRNA profile of 75 patients with IgA nephropathy and 75 healthy controls [",
"    <a class=\"abstract\" href=\"UTD.htm?19/48/20233/abstract/27\">",
"     27",
"    </a>",
"    ], the following findings were observed:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Leukocytes from patients with IgA nephropathy overexpressed a specific miRNA (miR-148b), and overexpression of miR-148b correlated with decreased expression of C1GAL-T1.",
"     </li>",
"     <li>",
"      The upregulation of miR-0148b was also associated with poor O-galactosylation of IgA1.",
"     </li>",
"     <li>",
"      The binding site for miR-0148b on the messenger RNA of C1GAL-T1 corresponded to the C1GAL-T1 polymorphism that was associated with IgA nephropathy in previous studies.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22581672\">",
"    <span class=\"h3\">",
"     Alterations of IgA1 sialylation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Changes in sialylation of IgA1 in IgAN are more contentious with increased and decreased O-sialylation being reported. Increased alpha2,3-linked and alpha2,6-linked sialylation of serum IgA1 have been reported and it has been suggested that this increase inhibits interaction with the ASGP-R resulting in a reduced rate of systemic clearance of IgA-immune complexes and persistence of these IgA-immune complexes in the circulation.",
"   </p>",
"   <p>",
"    IgA-immune complexes with a high sialic acid content bind mesangial cells more strongly, differentially upregulate mesangial cell integrins and nitric oxide synthesis, and induce apoptosis and suppress mesangial cell proliferation. In addition, it has been postulated that sialylated IgA1 is more likely to bind extracellular matrix components because of its net negative charge. In contrast, a number of studies have reported reduced sialylation of serum IgA1 and tonsillar IgA1 in IgAN. The significance of reduced IgA1 sialylation is equally contentious, with studies reporting that reduced sialylation plays a variable role in IgA1 self-aggregation and IgA-immune complex formation, mesangial cell proliferation and activation and histopathological phenotype in IgAN.",
"   </p>",
"   <p>",
"    Crucial to the interpretation of all these studies is the reliability and specificity of the lectins used to analyze the alpha2,3-linked and alpha2,6-linked sialic acid content of IgA1. Current mass spectrometry data support IgA1 being undersialylated in IgAN, whether this relates to the alpha2,3- or alpha2,6-linked sialic acid or both is unknown.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Source and regulation of pathogenic IgA synthesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The association of episodic visible hematuria with mucosal infections originally led to the hypothesis that IgA nephropathy was linked with abnormal mucosal antigen handling. This was supported by the observation that mesangial IgA and the increased IgA fraction in the serum are polymeric, which is normally produced at mucosal surfaces rather than in systemic immune sites. However, mucosal polymeric IgA plasma cell numbers are normal or even reduced in IgA nephropathy, and polymeric IgA antibody levels are not elevated in mucosal secretions [",
"    <a class=\"abstract\" href=\"UTD.htm?19/48/20233/abstract/28,29\">",
"     28,29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Mucosal IgA responses to mucosal antigen challenge are also reduced, compared with healthy controls. This mucosal hyporesponsiveness, while perhaps not clinically relevant, argues against the mucosal IgA system being the source of the pathogenic fraction of serum IgA.",
"   </p>",
"   <p>",
"    In contrast, there is an increase in polymeric IgA1 plasma cells in the bone marrow of patients with IgA nephropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?19/48/20233/abstract/29,30\">",
"     29,30",
"    </a>",
"    ], and systemic antigen challenge results in increased titers of circulating polymeric IgA1 antibodies with normal levels in mucosal secretions [",
"    <a class=\"abstract\" href=\"UTD.htm?19/48/20233/abstract/31-34\">",
"     31-34",
"    </a>",
"    ]. Thus, the overproduction of polymeric IgA1 is likely due to an aberrant systemic, and not mucosal, immune response to systemic and mucosal antigen challenges [",
"    <a class=\"abstract\" href=\"UTD.htm?19/48/20233/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to the bone marrow, the tonsils may also be a source of abnormal IgA that forms immune complexes and deposits in the glomeruli [",
"    <a class=\"abstract\" href=\"UTD.htm?19/48/20233/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. As examples, a number of in vitro studies have demonstrated synthesis of poorly galactosylated polymeric IgA1 by tonsillar B cells and there have been reports of a fall in serum levels of poorly galactosylated IgA following tonsillectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?19/48/20233/abstract/36\">",
"     36",
"    </a>",
"    ]. However, there is a range of opinions as to the importance of the tonsils in IgA nephropathy. The data evaluating the possible efficacy of tonsillectomy as a therapy for IgA nephropathy are presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/7/42106?source=see_link&amp;anchor=H28#H28\">",
"     \"Treatment and prognosis of IgA nephropathy\", section on 'Tonsillectomy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although the specific mechanisms that control IgA synthesis in the various immune sites are not well defined, systemic production of IgA appears to be under similar T cell control mechanisms to IgG production [",
"    <a class=\"abstract\" href=\"UTD.htm?19/48/20233/abstract/37\">",
"     37",
"    </a>",
"    ]. As with other immunoglobulin isotypes, Type 2 T cell cytokines (IL-4, 5 and 6) promote B cell class switching to IgA, and subsequent proliferation and differentiation of IgA producing cells. IgA production is also specifically and potently promoted by the cytokines IL-10 and TGF-b, which have suppressive effects on IgG production. The control of mucosal IgA production is less well understood, although Th2 T cells are undoubtedly involved. An imbalance of Type 1 and Type 2 T cell subsets has been proposed as an explanation for the dysregulated IgA responses seen in IgA nephropathy. In addition, there is provisional work suggesting that Type 1 and 2 cytokines differentially affect IgA1 O-glycosylation [",
"    <a class=\"abstract\" href=\"UTD.htm?19/48/20233/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A specific subpopulation of B lymphocytes (CD5+ CD19+ B cells) that do not require T cell regulation for immunoglobulin production have been implicated in a number of immune-mediated diseases. These lymphocytes are known to produce low affinity IgA with many of the features characteristic of pathogenic IgA, and are increased in the peripheral blood of patients with IgA nephropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?19/48/20233/abstract/39\">",
"     39",
"    </a>",
"    ]. Changes in CD5+ CD19+ B cell populations may underlie, in part, the dysregulated IgA secretion seen in IgA nephropathy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Impaired IgA clearance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Impaired systemic clearance of IgA promotes IgA deposition in the mesangium. Persistent mesangial IgA accumulation occurs by one or both of two mechanisms: the rate of IgA deposition exceeds the mesangial clearance capacity; or the deposited IgA is resistant to mesangial clearance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Systemic clearance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alterations in systemic IgA and IgA-immune complex clearance mechanisms will facilitate their persistence in the serum. The liver plays an important role in IgA clearance from the circulation and radiolabeled IgA clearance studies suggest reduced hepatic clearance in IgA nephropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?19/48/20233/abstract/40\">",
"     40",
"    </a>",
"    ]. A second route of IgA clearance is through CD89, which is an Fc receptor for IgA [",
"    <a class=\"abstract\" href=\"UTD.htm?19/48/20233/abstract/41\">",
"     41",
"    </a>",
"    ]. IgA nephropathy is associated with down regulated CD89 expression on myeloid cells and decreased IgA binding to CD89 [",
"    <a class=\"abstract\" href=\"UTD.htm?19/48/20233/abstract/42,43\">",
"     42,43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Mesangial clearance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mesangial IgA deposition is not always associated with the development of glomerular inflammation. Furthermore, mesangial IgA deposition may be reversible, as suggested by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sequential biopsy studies of patients who underwent clinical remission was accompanied by disappearance of IgA deposits [",
"      <a class=\"abstract\" href=\"UTD.htm?19/48/20233/abstract/44\">",
"       44",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Mesangial IgA deposits disappear when kidneys with IgA nephropathy are inadvertently transplanted into recipients who originally did not have IgA nephropathy [",
"      <a class=\"abstract\" href=\"UTD.htm?19/48/20233/abstract/45\">",
"       45",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A proposed pathway for mesangial clearance is through mesangial cell receptor-mediated endocytosis and catabolism of IgA deposits. A number of candidate receptors on the mesangial cell have been described [",
"    <a class=\"abstract\" href=\"UTD.htm?19/48/20233/abstract/46-52\">",
"     46-52",
"    </a>",
"    ], including the transferrin receptor (CD71), which binds IgA and aberrantly glycosylated polymeric IgA1 [",
"    <a class=\"abstract\" href=\"UTD.htm?19/48/20233/abstract/51-53\">",
"     51-53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is possible that impaired binding of IgA to mesangial cell receptor(s) could lead to defective mesangial IgA clearance and thereby contribute to IgA accumulation and the development of glomerular injury.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Uteroglobin",
"    </span>",
"    &nbsp;&mdash;&nbsp;IgA-containing immune complexes are commonly bound to fibronectin [",
"    <a class=\"abstract\" href=\"UTD.htm?19/48/20233/abstract/54\">",
"     54",
"    </a>",
"    ]. Mice in which the expression of the antiinflammatory protein uteroglobin is prevented (by gene-knockout) or suppressed (by antisense technology) display many of the clinical and pathologic features of human IgA nephropathy, including circulating IgA-fibronectin immune complexes and glomerular deposition of IgA [",
"    <a class=\"abstract\" href=\"UTD.htm?19/48/20233/abstract/55\">",
"     55",
"    </a>",
"    ]. The incubation of uteroglobin with IgA and fibronectin prevents the formation of IgA-fibronectin complexes.",
"   </p>",
"   <p>",
"    However, studies examining the possible role of uteroglobin in human IgA nephropathy have yielded inconsistent results [",
"    <a class=\"abstract\" href=\"UTD.htm?19/48/20233/abstract/56-59\">",
"     56-59",
"    </a>",
"    ]. A meta-analysis of six studies that included 930 patients and 768 healthy controls did not find a relationship between polymorphisms of the uteroglobin gene and either the development or progression of IgA nephropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?19/48/20233/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Development of glomerular injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;IgA nephropathy is generally not associated with a marked cellular glomerular infiltration, suggesting that glomerular injury is mediated by resident glomerular cells. While IgG and complement components are often codeposited, IgA alone appears sufficient to provoke glomerular injury in the susceptible individual. This occurs predominantly through IgA-induced activation of mesangial cells and local complement activation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     IgA-induced activation of mesangial cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;Polymeric IgA elicits a phenotypic transformation in mesangial cells in vitro, with mesangial cell proliferation and secretion of extracellular matrix components [",
"    <a class=\"abstract\" href=\"UTD.htm?19/48/20233/abstract/12\">",
"     12",
"    </a>",
"    ]. There is increased expression of transforming growth factor (TGF)-beta and components of the renin-angiotensin system in IgA nephropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?19/48/20233/abstract/61-64\">",
"     61-64",
"    </a>",
"    ]. In addition, polymeric IgA appears to stimulate the production of a variety of proinflammatory and profibrotic molecules, such as interleukin-6 [",
"    <a class=\"abstract\" href=\"UTD.htm?19/48/20233/abstract/12,65,66\">",
"     12,65,66",
"    </a>",
"    ]. Expression of platelet-derived growth factor (PDGF) B and D chains, proteins known to be important in the pathogenesis of mesangioproliferative glomerulonephritis, are upregulated in glomeruli in IgA nephropathy and have been shown in mouse models to induce marked mesangial cell proliferation [",
"    <a class=\"abstract\" href=\"UTD.htm?19/48/20233/abstract/67,68\">",
"     67,68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Codeposition of IgG may synergistically contribute to the development of a proinflammatory phenotype in mesangial cells and thereby influence the degree of glomerular injury [",
"    <a class=\"abstract\" href=\"UTD.htm?19/48/20233/abstract/2,69,70\">",
"     2,69,70",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Mesangial cell-podocyte crosstalk",
"    </span>",
"    &nbsp;&mdash;&nbsp;Emerging data support the influence of mesangial cell-derived soluble mediators (such as tumor necrosis factor (TNF)-alpha and TGF-beta) on podocyte phenotype (including expression of nephrin, ezrin and podocin, and TNF-alpha secretion) in IgA nephropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?19/48/20233/abstract/71-74\">",
"     71-74",
"    </a>",
"    ]. A progressive loss of podocyte markers has been shown to occur early at sites of capsular adhesions and in capillary loops [",
"    <a class=\"abstract\" href=\"UTD.htm?19/48/20233/abstract/75\">",
"     75",
"    </a>",
"    ]. IgA-induced mesangial cell activation may influence not only local changes within the mesangium but also glomerulotubular communication and the development of interstitial damage in IgA nephropathy through alterations in podocyte function.",
"   </p>",
"   <p>",
"    The loss of podocyte markers [",
"    <a class=\"abstract\" href=\"UTD.htm?19/48/20233/abstract/75\">",
"     75",
"    </a>",
"    ] and the early development of glomerular capsular adhesions [",
"    <a class=\"abstract\" href=\"UTD.htm?19/48/20233/abstract/76\">",
"     76",
"    </a>",
"    ] suggests the possibility that primary podocyte injury similar to that which occurs in primary focal and segmental glomerulosclerosis may be underlie many, if not most, cases of IgA nephropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?19/48/20233/abstract/77\">",
"     77",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Local complement activation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Local complement activation appears to influence the extent of glomerular injury. Mesangial IgA probably activates C3 through the mannose-binding lectin pathway, leading to the generation of C5b-9, which then promotes the production of inflammatory mediators and matrix proteins by mesangial cells [",
"    <a class=\"abstract\" href=\"UTD.htm?19/48/20233/abstract/78-80\">",
"     78-80",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/58/42920?source=see_link&amp;anchor=H14#H14\">",
"     \"Inherited disorders of the complement system\", section on 'MBL deficiency'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is also some evidence for systemic activation of complement in a subpopulation of patients with IgAN [",
"    <a class=\"abstract\" href=\"UTD.htm?19/48/20233/abstract/81\">",
"     81",
"    </a>",
"    ]. Elevated levels of split products of activated C3 have been reported, suggesting activation of the alternative pathway. A number of investigators have attempted to use serum complement levels as both a diagnostic marker of IgA nephropathy and a predictor of the extent of glomerular injury, without consistent success [",
"    <a class=\"abstract\" href=\"UTD.htm?19/48/20233/abstract/82\">",
"     82",
"    </a>",
"    ]. The precise relationship between systemic markers of complement activation and disease activity is currently poorly understood.",
"   </p>",
"   <p>",
"    C3 and mannose-binding lectin are also synthesized locally by mesangial cells and podocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?19/48/20233/abstract/83\">",
"     83",
"    </a>",
"    ]; it is possible that the binding of polymeric IgA to mesangial cells incites local complement activation independent of systemic complement activity. Mesangial cells also synthesize complement regulatory proteins, which may explain why C5b-9 generation in IgA nephropathy does not usually result in mesangiolysis. The contribution of this in situ complement synthesis and activation to progressive glomerular injury is unknown. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/30/18921?source=see_link\">",
"     \"Mechanisms of immune injury of the glomerulus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The etiology of IgA nephropathy is unknown in the great majority of cases. The possibility that infections contribute to the underlying pathogenesis of this disorder has been explored, as have genetic associations.",
"   </p>",
"   <p>",
"    It has also been suggested that IgA nephropathy results from hypersensitivity to food antigens, in view of its association with celiac disease. There is, however, no evidence for widespread hypersensitivity to food antigens in IgA nephropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?19/48/20233/abstract/84\">",
"     84",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In our opinion, IgA nephropathy results from dysregulation of mucosal-type IgA immune responses. As a result, any mucosal infection or food antigen may drive the production and release of pathogenic IgA into the circulation where it has the propensity to deposit within the mesangium and trigger glomerular injury.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;The provocation of visible hematuria by mucosal infection in patients with IgA nephropathy and the presumption that the mesangial IgA represented deposited immune complexes led to the view that IgA nephropathy was a complication of infection. Cytomegalovirus, Hemophilus parainfluenzae, Staphylococcus aureus (S. aureus), and Toxoplasmosis have been implicated [",
"    <a class=\"abstract\" href=\"UTD.htm?19/48/20233/abstract/85-91\">",
"     85-91",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As an example, in a clinical study from Japan, renal biopsy specimens from 116 patients with IgA nephropathy and 122 patients with other types of kidney disease were examined for the presence of S. aureus antigen in the glomeruli [",
"    <a class=\"abstract\" href=\"UTD.htm?19/48/20233/abstract/86\">",
"     86",
"    </a>",
"    ]. Although antigen was not detected in non-IgA disease, 68 percent of specimens from patients with IgA nephropathy had S. aureus cell envelope antigen localized with IgA antibody in the glomeruli. Another report from Japan suggested that, at least in that region, the inciting event may be pharyngeal colonization with Haemophilus parainfluenzae [",
"    <a class=\"abstract\" href=\"UTD.htm?19/48/20233/abstract/88\">",
"     88",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    With respect to a possible viral etiology, Mx-proteins in white blood cells, which are induced by type 1 interferon responses to viral infections, are not increased in IgA nephropathy, nor are Mx-protein deposits found in the glomeruli, as might have been expected if ongoing viral infection contributed to the pathogenesis of IgA nephropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?19/48/20233/abstract/92\">",
"     92",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While a number of different exogenous antigens have been identified in glomerular deposits in IgA nephropathy, this observation is not consistently reported across all studies. As a result, it seems more probable that the development of IgA nephropathy is a consequence of aberrant IgA immune response rather than the antigen (infecting organism) itself.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Genetic predisposition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although IgA nephropathy is considered a sporadic disease, its presence among certain families suggests there may be a genetic predisposition, at least in some individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?19/48/20233/abstract/93\">",
"     93",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A familial incidence has been described in the United States (in eastern Kentucky) and elsewhere [",
"    <a class=\"abstract\" href=\"UTD.htm?19/48/20233/abstract/94-99\">",
"     94-99",
"    </a>",
"    ]. This relationship may be independent of environmental factors and may reflect an inherited susceptibility to develop mesangial glomerulonephritis. One study in Italy, for example, studied 269 asymptomatic, first-degree relatives of patients with IgA nephropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?19/48/20233/abstract/95\">",
"     95",
"    </a>",
"    ]. Persistent microscopic hematuria was found in 42 patients (15.6 percent); biopsy confirmed the presence of IgA nephropathy in four of these patients.",
"   </p>",
"   <p>",
"    Familial IgA nephropathy is most likely due to variants in multiple loci [",
"    <a class=\"abstract\" href=\"UTD.htm?19/48/20233/abstract/24,99-102\">",
"     24,99-102",
"    </a>",
"    ]. The following associations have been made:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Three genome-wide association studies (GWAS) have identified loci associated with IgAN within the major histocompatibility complex [",
"      <a class=\"abstract\" href=\"UTD.htm?19/48/20233/abstract/24-26\">",
"       24-26",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A GWAS that included 3144 IgA nephropathy patients of Chinese and European ancestry also identified five independently associated loci including a region containing a deletion of CFHR1 and CFHR3 at chromosome 1q32, and a locus at chromosome 22q12 [",
"      <a class=\"abstract\" href=\"UTD.htm?19/48/20233/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A GWAS that included 4137 Chinese patients with IgAN identified loci at 17p13 and 8p23 [",
"      <a class=\"abstract\" href=\"UTD.htm?19/48/20233/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Another significant susceptibility locus that appears to be important in familial forms of IgA nephropathy is on chromosome 6q22-23 [",
"      <a class=\"abstract\" href=\"UTD.htm?19/48/20233/abstract/99\">",
"       99",
"      </a>",
"      ]. Linkage to this locus (called IGAN1) was identified by genome-wide analysis of 30 kindreds from Italy and the United States [",
"      <a class=\"abstract\" href=\"UTD.htm?19/48/20233/abstract/99\">",
"       99",
"      </a>",
"      ]. The gene products are not known and there are no obvious candidate genes within the linked intervals. A single nucleotide polymorphism association study of sporadic IgA nephropathy among patients from North America, France, and Finland failed to see a strong or consistent association signal within the IGAN1 critical interval [",
"      <a class=\"abstract\" href=\"UTD.htm?19/48/20233/abstract/103\">",
"       103",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Single nucleotide polymorphisms of megsin, a mesangial cell derived protein that is upregulated in glomeruli undergoing mesangial cell proliferation and mesangial matrix expansion, have been variably associated with severity and rate of progression of IgA nephropathy [",
"      <a class=\"abstract\" href=\"UTD.htm?19/48/20233/abstract/104-107\">",
"       104-107",
"      </a>",
"      ]. The relationship of megsin SNPs to susceptibility to develop IgA nephropathy is less clear [",
"      <a class=\"abstract\" href=\"UTD.htm?19/48/20233/abstract/104,108\">",
"       104,108",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Several cytokine and growth factor polymorphisms have been associated with susceptibility to, or prognosis of, IgAN [",
"    <a class=\"abstract\" href=\"UTD.htm?19/48/20233/abstract/109\">",
"     109",
"    </a>",
"    ]. However data from these limited studies have been contradictory and do not allow firm conclusions to be drawn.",
"   </p>",
"   <p>",
"    The frequency of subclinical IgA nephropathy in supposedly \"normal\" control populations means that most of the genetic studies thus far reported are examining clinical expression and not susceptibility to disease. In addition, most of these studies suffer from not having taken into account the phenomenon of \"population stratification\", and thus may represent \"false positives\" due to ancestry.",
"   </p>",
"   <p>",
"    Genetic study of IgA nephropathy is further complicated by the uncertainty as to whether IgA nephropathy is truly a single entity and the presence of subclinical IgA nephropathy in apparently normal control populations. Taken together, available genetic studies suggest that IgA nephropathy is a genetically heterogeneous entity that does not have classic Mendelian inheritance attributable to a single gene locus but is a complex polygenic disease probably involving both major histocompatibility complex (MHC) and non-MHC susceptibility alleles.",
"   </p>",
"   <p>",
"    With the genetic characterization of the enzymes responsible for O-glycosylation of IgA1, it has become possible to study changes in the O-glycosylation of IgA1 at a genetic level. Two case-control association studies have looked at single-nucleotide polymorphisms in C1Gal-T1 (or Core 1 b1,3-galactosyltransferase 1, which is one of the enzymes responsible for O-galactosylation of IgA1). These studies reported that polymorphisms of the C1Gal-T1 gene are associated with a genetic susceptibility to IgAN in Chinese and Italian populations [",
"    <a class=\"abstract\" href=\"UTD.htm?19/48/20233/abstract/110,111\">",
"     110,111",
"    </a>",
"    ]. It is not clear how these polymorphisms relate to changes in the functional activity of C1Gal-T1.",
"   </p>",
"   <p>",
"    A C1Gal-T1 chaperone protein, Cosmc also mediates IgA O-galactosylation. A study from Germany reported no evidence for a role for Cosmc mutations in IgAN [",
"    <a class=\"abstract\" href=\"UTD.htm?19/48/20233/abstract/112\">",
"     112",
"    </a>",
"    ]. What is clear from the available evidence is that patients with IgAN can produce IgD and IgA1 which is normally galactosylated, specifically those IgA1 antibodies directed against systemic antigens. Therefore, it is unlikely that there is a common, functionally significant, somatic mutation in genes encoding for the O-galactosylation of all proteins, and in particular IgA1, in IgAN.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The etiology of primary IgA nephropathy is generally unknown. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Etiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The initiating event in the pathogenesis of IgA nephropathy is the mesangial deposition of IgA, which is predominantly polymeric IgA of the IgA1 subclass (polymeric IgA1). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Mechanism of injury'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The factors that lead to development of disease are poorly understood, but are thought to include dysregulated synthesis and metabolism of IgA (resulting in IgA immune complexes with characteristics that favor mesangial deposition), and the mesangial cell reaction to mesangial IgA accumulation. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Mechanism of injury'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Environmental factors including dietary antigens and mucosal infections may drive the generation of pathogenic IgA immune complexes due to a dysregulated mucosal immune system. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Etiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      IgA nephropathy is a complex polygenic disease that involves both major histocompatibility complex (MHC) and non-MHC susceptibility alleles. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Genetic predisposition'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20233/abstract/1\">",
"      D'Amico G. Natural history of idiopathic IgA nephropathy and factors predictive of disease outcome. Semin Nephrol 2004; 24:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20233/abstract/2\">",
"      Emancipator SN. IgA nephropathy: morphologic expression and pathogenesis. Am J Kidney Dis 1994; 23:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20233/abstract/3\">",
"      Galla JH. IgA nephropathy. Kidney Int 1995; 47:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20233/abstract/4\">",
"      Donadio JV, Grande JP. IgA nephropathy. N Engl J Med 2002; 347:738.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20233/abstract/5\">",
"      Li LS, Liu ZH. Epidemiologic data of renal diseases from a single unit in China: analysis based on 13,519 renal biopsies. Kidney Int 2004; 66:920.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20233/abstract/6\">",
"      Simon P, Ramee MP, Boulahrouz R, et al. Epidemiologic data of primary glomerular diseases in western France. Kidney Int 2004; 66:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20233/abstract/7\">",
"      Barratt J, Feehally J. IgA nephropathy. J Am Soc Nephrol 2005; 16:2088.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20233/abstract/8\">",
"      Suzuki K, Honda K, Tanabe K, et al. Incidence of latent mesangial IgA deposition in renal allograft donors in Japan. Kidney Int 2003; 63:2286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20233/abstract/9\">",
"      Waldherr R, Rambausek M, Duncker WD, Ritz E. Frequency of mesangial IgA deposits in a non-selected autopsy series. Nephrol Dial Transplant 1989; 4:943.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20233/abstract/10\">",
"      Oortwijn BD, Rastaldi MP, Roos A, et al. Demonstration of secretory IgA in kidneys of patients with IgA nephropathy. Nephrol Dial Transplant 2007; 22:3191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20233/abstract/11\">",
"      Lee HS, Choi Y, Lee JS, et al. Ultrastructural changes in IgA nephropathy in relation to histologic and clinical data. Kidney Int 1989; 35:880.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20233/abstract/12\">",
"      Barratt J, Feehally J, Smith AC. Pathogenesis of IgA nephropathy. Semin Nephrol 2004; 24:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20233/abstract/13\">",
"      Hiki Y, Odani H, Takahashi M, et al. Mass spectrometry proves under-O-glycosylation of glomerular IgA1 in IgA nephropathy. Kidney Int 2001; 59:1077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20233/abstract/14\">",
"      Allen AC, Bailey EM, Brenchley PE, et al. Mesangial IgA1 in IgA nephropathy exhibits aberrant O-glycosylation: observations in three patients. Kidney Int 2001; 60:969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20233/abstract/15\">",
"      Smith AC, Molyneux K, Feehally J, Barratt J. O-glycosylation of serum IgA1 antibodies against mucosal and systemic antigens in IgA nephropathy. J Am Soc Nephrol 2006; 17:3520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20233/abstract/16\">",
"      Berthoux F, Suzuki H, Thibaudin L, et al. Autoantibodies targeting galactose-deficient IgA1 associate with progression of IgA nephropathy. J Am Soc Nephrol 2012; 23:1579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20233/abstract/17\">",
"      Lau KK, Wyatt RJ, Moldoveanu Z, et al. Serum levels of galactose-deficient IgA in children with IgA nephropathy and Henoch-Sch&ouml;nlein purpura. Pediatr Nephrol 2007; 22:2067.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20233/abstract/18\">",
"      Suzuki H, Moldoveanu Z, Hall S, et al. IgA1-secreting cell lines from patients with IgA nephropathy produce aberrantly glycosylated IgA1. J Clin Invest 2008; 118:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20233/abstract/19\">",
"      Novak J, Julian BA, Tomana M, Mestecky J. IgA glycosylation and IgA immune complexes in the pathogenesis of IgA nephropathy. Semin Nephrol 2008; 28:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20233/abstract/20\">",
"      Suzuki H, Fan R, Zhang Z, et al. Aberrantly glycosylated IgA1 in IgA nephropathy patients is recognized by IgG antibodies with restricted heterogeneity. J Clin Invest 2009; 119:1668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20233/abstract/21\">",
"      Tomana M, Novak J, Julian BA, et al. Circulating immune complexes in IgA nephropathy consist of IgA1 with galactose-deficient hinge region and antiglycan antibodies. J Clin Invest 1999; 104:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20233/abstract/22\">",
"      Kokubo T, Hiki Y, Iwase H, et al. Protective role of IgA1 glycans against IgA1 self-aggregation and adhesion to extracellular matrix proteins. J Am Soc Nephrol 1998; 9:2048.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20233/abstract/23\">",
"      Gharavi AG, Moldoveanu Z, Wyatt RJ, et al. Aberrant IgA1 glycosylation is inherited in familial and sporadic IgA nephropathy. J Am Soc Nephrol 2008; 19:1008.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20233/abstract/24\">",
"      Feehally J, Farrall M, Boland A, et al. HLA has strongest association with IgA nephropathy in genome-wide analysis. J Am Soc Nephrol 2010; 21:1791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20233/abstract/25\">",
"      Gharavi AG, Kiryluk K, Choi M, et al. Genome-wide association study identifies susceptibility loci for IgA nephropathy. Nat Genet 2011; 43:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20233/abstract/26\">",
"      Yu XQ, Li M, Zhang H, et al. A genome-wide association study in Han Chinese identifies multiple susceptibility loci for IgA nephropathy. Nat Genet 2012; 44:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20233/abstract/27\">",
"      Serino G, Sallustio F, Cox SN, et al. Abnormal miR-148b expression promotes aberrant glycosylation of IgA1 in IgA nephropathy. J Am Soc Nephrol 2012; 23:814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20233/abstract/28\">",
"      Harper SJ, Pringle JH, Wicks AC, et al. Expression of J chain mRNA in duodenal IgA plasma cells in IgA nephropathy. Kidney Int 1994; 45:836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20233/abstract/29\">",
"      Westberg NG, Baklien K, Schmekel B, et al. Quantitation of immunoglobulin-producing cells in small intestinal mucosa of patients with IgA nephropathy. Clin Immunol Immunopathol 1983; 26:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20233/abstract/30\">",
"      Harper SJ, Allen AC, Pringle JH, Feehally J. Increased dimeric IgA producing B cells in the bone marrow in IgA nephropathy determined by in situ hybridisation for J chain mRNA. J Clin Pathol 1996; 49:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20233/abstract/31\">",
"      van den Wall Bake AW, Daha MR, Evers-Schouten J, van Es LA. Serum IgA and the production of IgA by peripheral blood and bone marrow lymphocytes in patients with primary IgA nephropathy: evidence for the bone marrow as the source of mesangial IgA. Am J Kidney Dis 1988; 12:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20233/abstract/32\">",
"      Barratt J, Bailey EM, Buck KS, et al. Exaggerated systemic antibody response to mucosal Helicobacter pylori infection in IgA nephropathy. Am J Kidney Dis 1999; 33:1049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20233/abstract/33\">",
"      de Fijter JW, Eijgenraam JW, Braam CA, et al. Deficient IgA1 immune response to nasal cholera toxin subunit B in primary IgA nephropathy. Kidney Int 1996; 50:952.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20233/abstract/34\">",
"      Layward L, Allen AC, Hattersley JM, et al. Response to mucosal antigen challenge in IgA nephropathy. Exp Nephrol 1995; 3:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20233/abstract/35\">",
"      B&eacute;n&eacute; MC, Faure GC, Hurault de Ligny B, de March AK. Clinical involvement of the tonsillar immune system in IgA nephropathy. Acta Otolaryngol Suppl 2004; :10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20233/abstract/36\">",
"      Xie Y, Chen X, Nishi S, et al. Relationship between tonsils and IgA nephropathy as well as indications of tonsillectomy. Kidney Int 2004; 65:1135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20233/abstract/37\">",
"      Roodnat JI, de Fijter JW, van Kooten C, et al. Decreased IgA1 response after primary oral immunization with live typhoid vaccine in primary IgA nephropathy. Nephrol Dial Transplant 1999; 14:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20233/abstract/38\">",
"      Yamada K, Kobayashi N, Ikeda T, et al. Down-regulation of core 1 beta1,3-galactosyltransferase and Cosmc by Th2 cytokine alters O-glycosylation of IgA1. Nephrol Dial Transplant 2010; 25:3890.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20233/abstract/39\">",
"      Yuling H, Ruijing X, Xiang J, et al. CD19+CD5+ B cells in primary IgA nephropathy. J Am Soc Nephrol 2008; 19:2130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20233/abstract/40\">",
"      Roccatello D, Picciotto G, Coppo R, et al. The fate of aggregated immunoglobulin A injected in IgA nephropathy patients and healthy controls. Am J Kidney Dis 1991; 18:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20233/abstract/41\">",
"      Monteiro RC, Van De Winkel JG. IgA Fc receptors. Annu Rev Immunol 2003; 21:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20233/abstract/42\">",
"      Grosset&ecirc;te B, Launay P, Lehuen A, et al. Down-regulation of Fc alpha receptors on blood cells of IgA nephropathy patients: evidence for a negative regulatory role of serum IgA. Kidney Int 1998; 53:1321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20233/abstract/43\">",
"      van Zandbergen G, van Kooten C, Mohamad NK, et al. Reduced binding of immunoglobulin A (IgA) from patients with primary IgA nephropathy to the myeloid IgA Fc-receptor, CD89. Nephrol Dial Transplant 1998; 13:3058.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20233/abstract/44\">",
"      Hotta O, Furuta T, Chiba S, et al. Regression of IgA nephropathy: a repeat biopsy study. Am J Kidney Dis 2002; 39:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20233/abstract/45\">",
"      Cuevas X, Lloveras J, Mir M, et al. Disappearance of mesangial IgA deposits from the kidneys of two donors after transplantation. Transplant Proc 1987; 19:2208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20233/abstract/46\">",
"      Haddad E, Moura IC, Arcos-Fajardo M, et al. Enhanced expression of the CD71 mesangial IgA1 receptor in Berger disease and Henoch-Sch&ouml;nlein nephritis: association between CD71 expression and IgA deposits. J Am Soc Nephrol 2003; 14:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20233/abstract/47\">",
"      G&oacute;mez-Guerrero C, Duque N, Egido J. Mesangial cells possess an asialoglycoprotein receptor with affinity for human immunoglobulin A. J Am Soc Nephrol 1998; 9:568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20233/abstract/48\">",
"      McDonald KJ, Cameron AJ, Allen JM, Jardine AG. Expression of Fc alpha/mu receptor by human mesangial cells: a candidate receptor for immune complex deposition in IgA nephropathy. Biochem Biophys Res Commun 2002; 290:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20233/abstract/49\">",
"      Barratt J, Greer MR, Pawluczyk IZ, et al. Identification of a novel Fcalpha receptor expressed by human mesangial cells. Kidney Int 2000; 57:1936.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20233/abstract/50\">",
"      G&oacute;mez-Guerrero C, L&oacute;pez-Armada MJ, Gonz&aacute;lez E, Egido J. Soluble IgA and IgG aggregates are catabolized by cultured rat mesangial cells and induce production of TNF-alpha and IL-6, and proliferation. J Immunol 1994; 153:5247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20233/abstract/51\">",
"      Moura IC, Centelles MN, Arcos-Fajardo M, et al. Identification of the transferrin receptor as a novel immunoglobulin (Ig)A1 receptor and its enhanced expression on mesangial cells in IgA nephropathy. J Exp Med 2001; 194:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20233/abstract/52\">",
"      Moura IC, Arcos-Fajardo M, Sadaka C, et al. Glycosylation and size of IgA1 are essential for interaction with mesangial transferrin receptor in IgA nephropathy. J Am Soc Nephrol 2004; 15:622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20233/abstract/53\">",
"      Moura IC, Arcos-Fajardo M, Gdoura A, et al. Engagement of transferrin receptor by polymeric IgA1: evidence for a positive feedback loop involving increased receptor expression and mesangial cell proliferation in IgA nephropathy. J Am Soc Nephrol 2005; 16:2667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20233/abstract/54\">",
"      Jennette JC, Wieslander J, Tuttle R, Falk RJ. Serum IgA-fibronectin aggregates in patients with IgA nephropathy and Henoch-Sch&ouml;nlein purpura: diagnostic value and pathogenic implications. The Glomerular Disease Collaborative Network. Am J Kidney Dis 1991; 18:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20233/abstract/55\">",
"      Zheng F, Kundu GC, Zhang Z, et al. Uteroglobin is essential in preventing immunoglobulin A nephropathy in mice. Nat Med 1999; 5:1018.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20233/abstract/56\">",
"      Szelestei T, B&auml;hring S, Kov&aacute;cs T, et al. Association of a uteroglobin polymorphism with rate of progression in patients with IgA nephropathy. Am J Kidney Dis 2000; 36:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20233/abstract/57\">",
"      Coppo R, Chiesa M, Cirina P, et al. In human IgA nephropathy uteroglobin does not play the role inferred from transgenic mice. Am J Kidney Dis 2002; 40:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20233/abstract/58\">",
"      Narita I, Saito N, Goto S, et al. Role of uteroglobin G38A polymorphism in the progression of IgA nephropathy in Japanese patients. Kidney Int 2002; 61:1853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20233/abstract/59\">",
"      Kim YS, Kang D, Kwon DY, et al. Uteroglobin gene polymorphisms affect the progression of immunoglobulin A nephropathy by modulating the level of uteroglobin expression. Pharmacogenetics 2001; 11:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20233/abstract/60\">",
"      Yong D, QingQing W, Hua L, et al. Association of uteroglobin G38A polymorphism with IgA nephropathy: a meta-analysis. Am J Kidney Dis 2006; 48:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20233/abstract/61\">",
"      Lai KN, Tang SC, Guh JY, et al. Polymeric IgA1 from patients with IgA nephropathy upregulates transforming growth factor-beta synthesis and signal transduction in human mesangial cells via the renin-angiotensin system. J Am Soc Nephrol 2003; 14:3127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20233/abstract/62\">",
"      Del Prete D, Gambaro G, Lupo A, et al. Precocious activation of genes of the renin-angiotensin system and the fibrogenic cascade in IgA glomerulonephritis. Kidney Int 2003; 64:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20233/abstract/63\">",
"      Lai KN, Chan LY, Tang SC, et al. Mesangial expression of angiotensin II receptor in IgA nephropathy and its regulation by polymeric IgA1. Kidney Int 2004; 66:1403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20233/abstract/64\">",
"      Miyake-Ogawa C, Miyazaki M, Abe K, et al. Tissue-specific expression of renin-angiotensin system components in IgA nephropathy. Am J Nephrol 2005; 25:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20233/abstract/65\">",
"      van den Dobbelsteen ME, van der Woude FJ, Schroeijers WE, et al. Binding of dimeric and polymeric IgA to rat renal mesangial cells enhances the release of interleukin 6. Kidney Int 1994; 46:512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20233/abstract/66\">",
"      Horii Y, Iwano M, Hirata E, et al. Role of interleukin-6 in the progression of mesangial proliferative glomerulonephritis. Kidney Int Suppl 1993; 39:S71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20233/abstract/67\">",
"      Floege J, van Roeyen C, Boor P, Ostendorf T. The role of PDGF-D in mesangioproliferative glomerulonephritis. Contrib Nephrol 2007; 157:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20233/abstract/68\">",
"      Terada Y, Yamada T, Nakashima O, et al. Expression of PDGF and PDGF receptor mRNA in glomeruli in IgA nephropathy. J Am Soc Nephrol 1997; 8:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20233/abstract/69\">",
"      Rauterberg EW, Lieberknecht HM, Wingen AM, Ritz E. Complement membrane attack (MAC) in idiopathic IgA-glomerulonephritis. Kidney Int 1987; 31:820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20233/abstract/70\">",
"      O'Donoghue DJ, Darvill A, Ballardie FW. Mesangial cell autoantigens in immunoglobulin A nephropathy and Henoch-Sch&ouml;nlein purpura. J Clin Invest 1991; 88:1522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20233/abstract/71\">",
"      Lai KN, Leung JC, Chan LY, et al. Podocyte injury induced by mesangial-derived cytokines in IgA nephropathy. Nephrol Dial Transplant 2009; 24:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20233/abstract/72\">",
"      Lai KN, Leung JC, Chan LY, et al. Activation of podocytes by mesangial-derived TNF-alpha: glomerulo-podocytic communication in IgA nephropathy. Am J Physiol Renal Physiol 2008; 294:F945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20233/abstract/73\">",
"      Ye ZC, Wang C, Tang Y, et al. Serum IgA1 from patients with IgA nephropathy up-regulates integrin-linked kinase synthesis and inhibits adhesive capacity in podocytes through indirect pathways. Clin Invest Med 2009; 32:E20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20233/abstract/74\">",
"      Wang C, Ye Z, Peng H, et al. Effect of aggregated immunoglobulin A1 from immunoglobulin A nephropathy patients on nephrin expression in podocytes. Nephrology (Carlton) 2009; 14:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20233/abstract/75\">",
"      Hill GS, Karoui KE, Karras A, et al. Focal segmental glomerulosclerosis plays a major role in the progression of IgA nephropathy. I. Immunohistochemical studies. Kidney Int 2011; 79:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20233/abstract/76\">",
"      El Karoui K, Hill GS, Karras A, et al. Focal segmental glomerulosclerosis plays a major role in the progression of IgA nephropathy. II. Light microscopic and clinical studies. Kidney Int 2011; 79:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20233/abstract/77\">",
"      Cook HT. Focal segmental glomerulosclerosis in IgA nephropathy: a result of primary podocyte injury? Kidney Int 2011; 79:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20233/abstract/78\">",
"      Hisano S, Matsushita M, Fujita T, et al. Mesangial IgA2 deposits and lectin pathway-mediated complement activation in IgA glomerulonephritis. Am J Kidney Dis 2001; 38:1082.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20233/abstract/79\">",
"      Roos A, Rastaldi MP, Calvaresi N, et al. Glomerular activation of the lectin pathway of complement in IgA nephropathy is associated with more severe renal disease. J Am Soc Nephrol 2006; 17:1724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20233/abstract/80\">",
"      Matsuda M, Shikata K, Wada J, et al. Deposition of mannan binding protein and mannan binding protein-mediated complement activation in the glomeruli of patients with IgA nephropathy. Nephron 1998; 80:408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20233/abstract/81\">",
"      Seelen MA, Roos A, Daha MR. Role of complement in innate and autoimmunity. J Nephrol 2005; 18:642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20233/abstract/82\">",
"      Zwirner J, Burg M, Schulze M, et al. Activated complement C3: a potentially novel predictor of progressive IgA nephropathy. Kidney Int 1997; 51:1257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20233/abstract/83\">",
"      Montinaro V, Gesualdo L, Ranieri E, et al. Renal cortical complement C3 gene expression in IgA nephropathy. J Am Soc Nephrol 1997; 8:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20233/abstract/84\">",
"      Russell MW, Mestecky J, Julian BA, Galla JH. IgA-associated renal diseases: antibodies to environmental antigens in sera and deposition of immunoglobulins and antigens in glomeruli. J Clin Immunol 1986; 6:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20233/abstract/85\">",
"      Sharmin S, Shimizu Y, Hagiwara M, et al. Staphylococcus aureus antigens induce IgA-type glomerulonephritis in Balb/c mice. J Nephrol 2004; 17:504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20233/abstract/86\">",
"      Koyama A, Sharmin S, Sakurai H, et al. Staphylococcus aureus cell envelope antigen is a new candidate for the induction of IgA nephropathy. Kidney Int 2004; 66:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20233/abstract/87\">",
"      Nasr SH, Markowitz GS, Whelan JD, et al. IgA-dominant acute poststaphylococcal glomerulonephritis complicating diabetic nephropathy. Hum Pathol 2003; 34:1235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20233/abstract/88\">",
"      Suzuki S, Nakatomi Y, Sato H, et al. Haemophilus parainfluenzae antigen and antibody in renal biopsy samples and serum of patients with IgA nephropathy. Lancet 1994; 343:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20233/abstract/89\">",
"      Waldo FB, Britt WJ, Tomana M, et al. Non-specific mesangial staining with antibodies against cytomegalovirus in immunoglobulin-A nephropathy. Lancet 1989; 1:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20233/abstract/90\">",
"      Park JS, Song JH, Yang WS, et al. Cytomegalovirus is not specifically associated with immunoglobulin A nephropathy. J Am Soc Nephrol 1994; 4:1623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20233/abstract/91\">",
"      Satoskar AA, Nadasdy G, Plaza JA, et al. Staphylococcus infection-associated glomerulonephritis mimicking IgA nephropathy. Clin J Am Soc Nephrol 2006; 1:1179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20233/abstract/92\">",
"      Floege J, Burg M, Al Masri AN, et al. Expression of interferon-inducible Mx-proteins in patients with IgA nephropathy or Henoch-Sch&ouml;nlein purpura. Am J Kidney Dis 1999; 33:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20233/abstract/93\">",
"      Frimat L, Kessler M. Controversies concerning the importance of genetic polymorphism in IgA nephropathy. Nephrol Dial Transplant 2002; 17:542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20233/abstract/94\">",
"      Julian BA, Quiggins PA, Thompson JS, et al. Familial IgA nephropathy. Evidence of an inherited mechanism of disease. N Engl J Med 1985; 312:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20233/abstract/95\">",
"      Schena FP. Immunogenetic aspects of primary IgA nephropathy. Kidney Int 1995; 48:1998.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20233/abstract/96\">",
"      Scolari F, Amoroso A, Savoldi S, et al. Familial clustering of IgA nephropathy: further evidence in an Italian population. Am J Kidney Dis 1999; 33:857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20233/abstract/97\">",
"      Hsu SI, Ramirez SB, Winn MP, et al. Evidence for genetic factors in the development and progression of IgA nephropathy. Kidney Int 2000; 57:1818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20233/abstract/98\">",
"      Schena FP, Cerullo G, Rossini M, et al. Increased risk of end-stage renal disease in familial IgA nephropathy. J Am Soc Nephrol 2002; 13:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20233/abstract/99\">",
"      Gharavi AG, Yan Y, Scolari F, et al. IgA nephropathy, the most common cause of glomerulonephritis, is linked to 6q22-23. Nat Genet 2000; 26:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20233/abstract/100\">",
"      Bisceglia L, Cerullo G, Forabosco P, et al. Genetic heterogeneity in Italian families with IgA nephropathy: suggestive linkage for two novel IgA nephropathy loci. Am J Hum Genet 2006; 79:1130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20233/abstract/101\">",
"      Paterson AD, Liu XQ, Wang K, et al. Genome-wide linkage scan of a large family with IgA nephropathy localizes a novel susceptibility locus to chromosome 2q36. J Am Soc Nephrol 2007; 18:2408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20233/abstract/102\">",
"      Karnib HH, Sanna-Cherchi S, Zalloua PA, et al. Characterization of a large Lebanese family segregating IgA nephropathy. Nephrol Dial Transplant 2007; 22:772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20233/abstract/103\">",
"      Liu XQ, Paterson AD, He N, et al. IL5RA and TNFRSF6B gene variants are associated with sporadic IgA nephropathy. J Am Soc Nephrol 2008; 19:1025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20233/abstract/104\">",
"      Miyata T, Nangaku M, Suzuki D, et al. A mesangium-predominant gene, megsin, is a new serpin upregulated in IgA nephropathy. J Clin Invest 1998; 102:828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20233/abstract/105\">",
"      Li YJ, Du Y, Li CX, et al. Family-based association study showing that immunoglobulin A nephropathy is associated with the polymorphisms 2093C and 2180T in the 3' untranslated region of the Megsin gene. J Am Soc Nephrol 2004; 15:1739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20233/abstract/106\">",
"      Xia Y, Li Y, Du Y, et al. Association of MEGSIN 2093C-2180T haplotype at the 3' untranslated region with disease severity and progression of IgA nephropathy. Nephrol Dial Transplant 2006; 21:1570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20233/abstract/107\">",
"      Xia YF, Huang S, Li X, et al. A family-based association study of megsin A23167G polymorphism with susceptibility and progression of IgA nephropathy in a Chinese population. Clin Nephrol 2006; 65:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20233/abstract/108\">",
"      Suzuki D, Miyata T, Nangaku M, et al. Expression of megsin mRNA, a novel mesangium-predominant gene, in the renal tissues of various glomerular diseases. J Am Soc Nephrol 1999; 10:2606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20233/abstract/109\">",
"      Hsu SI. Racial and genetic factors in IgA nephropathy. Semin Nephrol 2008; 28:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20233/abstract/110\">",
"      Li, GS, Zhang, H, Lv, JC, et al. Variants of C1GALT1 gene are associated with the genetic susceptibility to IgA nephropathy. Kidney Int 2007; 71:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20233/abstract/111\">",
"      Pirulli D, Crovella S, Ulivi S, et al. Genetic variant of C1GalT1 contributes to the susceptibility to IgA nephropathy. J Nephrol 2009; 22:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/48/20233/abstract/112\">",
"      Malycha F, Eggermann T, Hristov M, et al. No evidence for a role of cosmc-chaperone mutations in European IgA nephropathy patients. Nephrol Dial Transplant 2009; 24:321.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3095 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-2.133.93.82-3DA446CC7F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_48_20233=[""].join("\n");
var outline_f19_48_20233=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MECHANISM OF INJURY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Characteristics of pathogenic IgA",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22581665\">",
"      - Poor O-galactosylation of IgA1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H22581759\">",
"      Causes of poor O-galactosylation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22581672\">",
"      - Alterations of IgA1 sialylation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Source and regulation of pathogenic IgA synthesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Impaired IgA clearance",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Systemic clearance",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Mesangial clearance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Uteroglobin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Development of glomerular injury",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - IgA-induced activation of mesangial cells",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Mesangial cell-podocyte crosstalk",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Local complement activation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Infections",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Genetic predisposition",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/19/1337?source=related_link\">",
"      Clinical presentation and diagnosis of IgA nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/6/41066?source=related_link\">",
"      Epidemiology, classification, and pathogenesis of focal segmental glomerulosclerosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/58/42920?source=related_link\">",
"      Inherited disorders of the complement system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/30/18921?source=related_link\">",
"      Mechanisms of immune injury of the glomerulus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/47/39674?source=related_link\">",
"      Overview of gene expression profiling, proteomics, and microRNA profiling in clinical oncology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/19/26938?source=related_link\">",
"      Secondary factors and progression of chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/7/42106?source=related_link\">",
"      Treatment and prognosis of IgA nephropathy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_48_20234="Melasma forehead";
var content_f19_48_20234=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F75884%7EDERM%2F64109%7EDERM%2F52220&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F75884%7EDERM%2F64109%7EDERM%2F52220&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Melasma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Mottled hyperpigmented patches are present on the forehead.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Melasma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A mottled hyperpigmented patch is present on the cheek.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Melasma lip",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 325px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A hyperpigmented patch is present on the upper lip in this patient with melasma.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_48_20234=[""].join("\n");
var outline_f19_48_20234=null;
var title_f19_48_20235="Disorders with coll gn";
var content_f19_48_20235=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F72313&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F72313&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Disorders associated with collapsing glomerulopathy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Disorder",
"       </td>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Infection",
"       </td>",
"       <td>",
"        HIV, cytomegalovirus, parvovirus B1, pulmonary TB, leishmaniasis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Autoimmune",
"       </td>",
"       <td>",
"        Adult Still's disease, lupus-like syndrome, mixed connective tissue disorder, cerebral arteritis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Malignancy",
"       </td>",
"       <td>",
"        Multiple myeloma, acute monoblastic leukemia, hemophagocytic syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Genetic",
"       </td>",
"       <td>",
"        Action myoclonus-renal failure syndrome, mitochondrial cytopathy, familial, sickle cell disease, MYH9 and APOL1 gene polymorphisms",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Drug exposure",
"       </td>",
"       <td>",
"        Interferon-alpha, beta, or gamma; anabolic steroids, pamidronate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Post transplanation",
"       </td>",
"       <td>",
"        De novo, recurrent, arteriopathy, acute vascular rejection, thrombotic microangiopathy",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Albaqumi M, Soos TJ, Barisoni L, Nelson PJ. Collapsing glomerulopathy. J Am Soc Nephrol 2006; 17:2854.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_48_20235=[""].join("\n");
var outline_f19_48_20235=null;
var title_f19_48_20236="Evaluation chronic HBV";
var content_f19_48_20236=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F62875&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F62875&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Evaluation of patients with chronic HBV infection",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Initial evaluation",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       1. History and physical examination",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       2. Family History of liver disease, HCC",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       3. Laboratory tests to assess liver disease - complete blood counts with platelets, hepatic panel, and prothrombin time",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       4. Tests for HBV replication - HBeAg/anti-HBe, HBV DNA",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       5. Tests to rule out viral coinfections - anti-HCV, anti-HDV (in persons from countries where HDV infection is common and in those with history of injection drug use), and anti-HIV in those at risk",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       6. Tests to screen for HCC - AFP at baseline and, in high risk patients, ultrasound",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       7. Consider liver biopsy to grade and stage liver disease - for patients who meet criteria for chronic hepatitis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Suggested follow-up for patients not considered for treatment HBeAg+, HBV DNA &gt;20,000 int. units/mL and normal ALT",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       ALT every 3-6 months, more often if ALT becomes elevated",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       If ALT levels are between 1-2 x ULN, recheck ALT every 1-3 months; consider liver biopsy if age &gt;40, ALT borderline or mildly elevated on serial tests. Consider treatment if biopsy shows moderate/severe inflammation or significant fibrosis.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       If ALT &gt;2 x ULN for 3-6 months and HBeAg+, HBV DNA &gt;20,000 int. units/mL, consider liver biopsy and treatment",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Consider screening for HCC in relevant population",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Inactive HBsAg carrier state",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       ALT every 3 months for 1 year, if persistently normal, ALT every 6-12 months",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       If ALT &gt;1-2 x ULN, check serum HBV DNA level and exclude other causes of liver disease. Consider liver biopsy if ALT borderline or mildly elevated on serial tests or if HBV DNA persistently &ge;2000 int. units/mL. Consider treatment if biopsy shows moderate/severe inflammation or significant fibrosis.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Consider screening for HCC in relevant population",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Lok ASF, McMahon BJ. Chronic hepatitis B: Update 2009. Hepatology 2009; 50:661. Available online at file://publish.aasld.org/Pages/Default.aspx. Accessed September 8th 2009. Copyright &copy; 2009 American Association for the Study of Liver Diseases.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_48_20236=[""].join("\n");
var outline_f19_48_20236=null;
var title_f19_48_20237="Monosodium urate crystals";
var content_f19_48_20237=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F64391&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F64391&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Monosodium urate crystals",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 286px; height: 188px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Synovial fluid from a patient with acute gouty arthritis, when viewed with compensated polarized microscopy, reveals some needle shaped, birefringent crystals, one of which is aligned with the axis of the compensator, and is bright yellow.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ralph Schumacher, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_48_20237=[""].join("\n");
var outline_f19_48_20237=null;
var title_f19_48_20238="Outcome delayed rx";
var content_f19_48_20238=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F53517&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F53517&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Reported experience with deliberate delay of therapy for patients with invasive cervical cancer to allow for time for fetal maturity",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Author, year",
"      </td>",
"      <td class=\"subtitle1\">",
"       N",
"      </td>",
"      <td class=\"subtitle1\">",
"       Stage",
"      </td>",
"      <td class=\"subtitle1\">",
"       EGA at diagnosis",
"      </td>",
"      <td class=\"subtitle1\">",
"       EGA at delivery",
"      </td>",
"      <td class=\"subtitle1\">",
"       Delay in treatment (weeks)",
"      </td>",
"      <td class=\"subtitle1\">",
"       Disease progression",
"      </td>",
"      <td class=\"subtitle1\">",
"       Follow-up (month; mean/range)",
"      </td>",
"      <td class=\"subtitle1\">",
"       Maternal outcome",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Prem, 1966",
"      </td>",
"      <td>",
"       4",
"      </td>",
"      <td>",
"       I",
"      </td>",
"      <td>",
"       &ge; 28",
"      </td>",
"      <td>",
"       35-36",
"      </td>",
"      <td>",
"       6 (average)",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       All &gt; 60 months",
"      </td>",
"      <td>",
"       All NED",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Prem, 1966",
"      </td>",
"      <td>",
"       5",
"      </td>",
"      <td>",
"       I",
"      </td>",
"      <td>",
"       20-34",
"      </td>",
"      <td>",
"       34-38",
"      </td>",
"      <td>",
"       11-17",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       34-64",
"      </td>",
"      <td>",
"       All NED",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Boutselis, 1972",
"      </td>",
"      <td>",
"       5",
"      </td>",
"      <td>",
"       IA1",
"      </td>",
"      <td>",
"       8-24",
"      </td>",
"      <td>",
"       3rd trimester",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       72-180",
"      </td>",
"      <td>",
"       All NED",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Dudan, 1973",
"      </td>",
"      <td>",
"       2",
"      </td>",
"      <td>",
"       IB",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       8-24",
"      </td>",
"      <td>",
"       2",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       &ge; 1 DOD",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Thompson, 1975",
"      </td>",
"      <td>",
"       7",
"      </td>",
"      <td>",
"       IA",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       3rd trimester",
"      </td>",
"      <td>",
"       5-28",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       50 (3-120)",
"      </td>",
"      <td>",
"       All NED",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Lee, 1981",
"      </td>",
"      <td>",
"       9",
"      </td>",
"      <td>",
"       IA-II",
"      </td>",
"      <td>",
"       &ge; 24",
"      </td>",
"      <td>",
"       3rd trimester",
"      </td>",
"      <td>",
"       &lt; 12",
"      </td>",
"      <td>",
"       No",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       All NED",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Nisker, 1983",
"      </td>",
"      <td>",
"       1",
"      </td>",
"      <td>",
"       IB",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       3rd trimester",
"      </td>",
"      <td>",
"       24",
"      </td>",
"      <td>",
"       1",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       DOD",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Greer, 1989",
"      </td>",
"      <td>",
"       5",
"      </td>",
"      <td>",
"       IB",
"      </td>",
"      <td>",
"       20-24",
"      </td>",
"      <td>",
"       28-37",
"      </td>",
"      <td>",
"       6-17",
"      </td>",
"      <td>",
"       No",
"      </td>",
"      <td>",
"       23 (13-35)",
"      </td>",
"      <td>",
"       <p>",
"        4 NED",
"       </p>",
"       <p>",
"        1 DOD",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Monk, 1992",
"      </td>",
"      <td>",
"       4",
"      </td>",
"      <td>",
"       IA2-IB",
"      </td>",
"      <td>",
"       10-23",
"      </td>",
"      <td>",
"       3rd trimester",
"      </td>",
"      <td>",
"       10-23",
"      </td>",
"      <td>",
"       No",
"      </td>",
"      <td>",
"       40 (2-228)",
"      </td>",
"      <td>",
"       All NED",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Duggan, 1993",
"      </td>",
"      <td>",
"       8",
"      </td>",
"      <td>",
"       IA1-IB1",
"      </td>",
"      <td>",
"       11-31",
"      </td>",
"      <td>",
"       31-40",
"      </td>",
"      <td>",
"       8-30",
"      </td>",
"      <td>",
"       No",
"      </td>",
"      <td>",
"       33 (3-124)",
"      </td>",
"      <td>",
"       All NED",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Sorosky, 1995",
"      </td>",
"      <td>",
"       8",
"      </td>",
"      <td>",
"       IB1",
"      </td>",
"      <td>",
"       0-34*",
"      </td>",
"      <td>",
"       33-38",
"      </td>",
"      <td>",
"       3-40",
"      </td>",
"      <td>",
"       No",
"      </td>",
"      <td>",
"       33 (13-68)",
"      </td>",
"      <td>",
"       All NED",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Sorosky, 1996",
"      </td>",
"      <td>",
"       4&bull;",
"      </td>",
"      <td>",
"       IB1-IB2",
"      </td>",
"      <td>",
"       18-32",
"      </td>",
"      <td>",
"       35-36",
"      </td>",
"      <td>",
"       4-15",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       51 (12-120)",
"      </td>",
"      <td>",
"       <p>",
"        3 NED",
"       </p>",
"       <p>",
"        1 DOD",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Sood, 1996",
"      </td>",
"      <td>",
"       11",
"      </td>",
"      <td>",
"       IA1-IB1",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       3rd trimester",
"      </td>",
"      <td>",
"       3-32",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       118 (12-360)",
"      </td>",
"      <td>",
"       All NED",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Van Vliet, 1998",
"      </td>",
"      <td>",
"       4",
"      </td>",
"      <td>",
"       IB",
"      </td>",
"      <td>",
"       23-32",
"      </td>",
"      <td>",
"       32-35",
"      </td>",
"      <td>",
"       3-10",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       67 (16-106)",
"      </td>",
"      <td>",
"       All NED",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Takushi, 2002",
"      </td>",
"      <td>",
"       12",
"      </td>",
"      <td>",
"       IA1-IB2",
"      </td>",
"      <td>",
"       12-27",
"      </td>",
"      <td>",
"       30 - term",
"      </td>",
"      <td>",
"       6-25",
"      </td>",
"      <td>",
"       No",
"      </td>",
"      <td>",
"       70-156",
"      </td>",
"      <td>",
"       All NED",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Taen, 2006",
"      </td>",
"      <td>",
"       1",
"      </td>",
"      <td>",
"       IB1",
"      </td>",
"      <td>",
"       14",
"      </td>",
"      <td>",
"       31",
"      </td>",
"      <td>",
"       17",
"      </td>",
"      <td>",
"       No",
"      </td>",
"      <td>",
"       17",
"      </td>",
"      <td>",
"       NED",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Germann, 2005",
"      </td>",
"      <td>",
"       9",
"      </td>",
"      <td>",
"       IB1",
"      </td>",
"      <td>",
"       1st and 2nd trimester",
"      </td>",
"      <td>",
"       3rd trimester",
"      </td>",
"      <td>",
"       4-24 (16)",
"      </td>",
"      <td>",
"       No",
"      </td>",
"      <td>",
"       63 (2-168)",
"      </td>",
"      <td>",
"       All NED",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Lee, 2007",
"      </td>",
"      <td>",
"       11",
"      </td>",
"      <td>",
"       IA1-IIA",
"      </td>",
"      <td>",
"       6-31",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       4-34",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       <p>",
"        9 NED",
"       </p>",
"       <p>",
"        2 DOD",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Yahata, 2008",
"      </td>",
"      <td>",
"       4",
"      </td>",
"      <td>",
"       IA1&Delta;",
"      </td>",
"      <td>",
"       16-23",
"      </td>",
"      <td>",
"       37-41",
"      </td>",
"      <td>",
"       &gt;16-25",
"      </td>",
"      <td>",
"       No",
"      </td>",
"      <td>",
"       24-155",
"      </td>",
"      <td>",
"       All NED",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <strong>",
"        TOTAL",
"       </strong>",
"      </td>",
"      <td>",
"       <strong>",
"        98",
"       </strong>",
"      </td>",
"      <td>",
"       <strong>",
"        IA1-II",
"       </strong>",
"      </td>",
"      <td>",
"       <strong>",
"        0-34",
"       </strong>",
"      </td>",
"      <td>",
"       <strong>",
"        3rd trimester",
"       </strong>",
"      </td>",
"      <td>",
"       <strong>",
"        3-40",
"       </strong>",
"      </td>",
"      <td>",
"       <strong>",
"        3",
"       </strong>",
"      </td>",
"      <td>",
"       <strong>",
"        2-360",
"       </strong>",
"      </td>",
"      <td>",
"       <p>",
"        <strong>",
"         93 NED",
"        </strong>",
"       </p>",
"       <p>",
"        <strong>",
"         4 DOD",
"        </strong>",
"       </p>",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    In some cases treatment delay was greater than the time difference of diagnosis to delivery as post-delivery irradiation may not have started for several weeks postpartum.",
"    <div class=\"footnotes\">",
"     EGA: estimated gestational age; NED: no evidence of disease; DOD: dead of disease.",
"     <br>",
"      * One patient was diagnosed in the cycle prior to conception and followed through pregnancy.",
"      <br>",
"       &bull; Excluded 3 cases that were doubly reported in Sorosky's 1995 and 1996 series.",
"       <br>",
"        &Delta; All adenocarcinoma.",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced and modified with permission from: Nature Reviews. Karam A, Feldman N, Holschneider CH. Neoadjuvant cisplatin and radical cesarean hysterectomy for cervical cancer in pregnancy. Nat Clin Pract Oncol 2007; 4:375. Copyright &copy;2007 Macmillan Magazines Ltd.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.nature.com\">",
"      file://www.nature.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_48_20238=[""].join("\n");
var outline_f19_48_20238=null;
var title_f19_48_20239="Accuracy US acute appendicitis";
var content_f19_48_20239=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F59522&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F59522&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Sensitivity and specificity of ultrasonography in the detection of acute appendicitis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"8\" width=\"12%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Number of patients",
"       </td>",
"       <td class=\"subtitle1\">",
"        Sensitivity",
"       </td>",
"       <td class=\"subtitle1\">",
"        Specificity",
"       </td>",
"       <td class=\"subtitle1\">",
"        PPV",
"       </td>",
"       <td class=\"subtitle1\">",
"        NPV",
"       </td>",
"       <td class=\"subtitle1\">",
"        Study",
"       </td>",
"       <td class=\"subtitle1\">",
"        Author",
"       </td>",
"       <td class=\"subtitle1\">",
"        Year",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        70",
"       </td>",
"       <td class=\"centered\">",
"        94",
"       </td>",
"       <td class=\"centered\">",
"        89",
"       </td>",
"       <td class=\"centered\">",
"        89",
"       </td>",
"       <td class=\"centered\">",
"        94",
"       </td>",
"       <td class=\"centered\">",
"        [1]",
"       </td>",
"       <td class=\"centered\">",
"        Vignault F, et al",
"       </td>",
"       <td class=\"centered\">",
"        1990",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        857",
"       </td>",
"       <td class=\"centered\">",
"        90",
"       </td>",
"       <td class=\"centered\">",
"        98",
"       </td>",
"       <td class=\"centered\">",
"        94",
"       </td>",
"       <td class=\"centered\">",
"        97",
"       </td>",
"       <td class=\"centered\">",
"        [2]",
"       </td>",
"       <td class=\"centered\">",
"        Schwerk WB, et al",
"       </td>",
"       <td class=\"centered\">",
"        1990",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        462",
"       </td>",
"       <td class=\"centered\">",
"        77",
"       </td>",
"       <td class=\"centered\">",
"        NE",
"       </td>",
"       <td class=\"centered\">",
"        &gt;92",
"       </td>",
"       <td class=\"centered\">",
"        NE",
"       </td>",
"       <td class=\"centered\">",
"        [3]",
"       </td>",
"       <td class=\"centered\">",
"        Bendeck SE, et al",
"       </td>",
"       <td class=\"centered\">",
"        2002",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        283",
"       </td>",
"       <td class=\"centered\">",
"        86",
"       </td>",
"       <td class=\"centered\">",
"        95",
"       </td>",
"       <td class=\"centered\">",
"        91",
"       </td>",
"       <td class=\"centered\">",
"        92",
"       </td>",
"       <td class=\"centered\">",
"        [4]",
"       </td>",
"       <td class=\"centered\">",
"        Kaiser S, et al",
"       </td>",
"       <td class=\"centered\">",
"        2002",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        49*",
"       </td>",
"       <td class=\"centered\">",
"        84",
"       </td>",
"       <td class=\"centered\">",
"        96",
"       </td>",
"       <td class=\"centered\">",
"        90",
"       </td>",
"       <td class=\"centered\">",
"        NE",
"       </td>",
"       <td class=\"centered\">",
"        [5]",
"       </td>",
"       <td class=\"centered\">",
"        Sun SS, et al",
"       </td>",
"       <td class=\"centered\">",
"        2002",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        40",
"       </td>",
"       <td class=\"centered\">",
"        87",
"       </td>",
"       <td class=\"centered\">",
"        90",
"       </td>",
"       <td class=\"centered\">",
"        NE",
"       </td>",
"       <td class=\"centered\">",
"        NE",
"       </td>",
"       <td class=\"centered\">",
"        [6]",
"       </td>",
"       <td class=\"centered\">",
"        Chang CC, et al",
"       </td>",
"       <td class=\"centered\">",
"        2003",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        199",
"       </td>",
"       <td class=\"centered\">",
"        79",
"       </td>",
"       <td class=\"centered\">",
"        78",
"       </td>",
"       <td class=\"centered\">",
"        87",
"       </td>",
"       <td class=\"centered\">",
"        65",
"       </td>",
"       <td class=\"centered\">",
"        [7]",
"       </td>",
"       <td class=\"centered\">",
"        Poortman P, et al",
"       </td>",
"       <td class=\"centered\">",
"        2003",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        174",
"       </td>",
"       <td class=\"centered\">",
"        100",
"       </td>",
"       <td class=\"centered\">",
"        37",
"       </td>",
"       <td class=\"centered\">",
"        50",
"       </td>",
"       <td class=\"centered\">",
"        100",
"       </td>",
"       <td class=\"centered\">",
"        [8]",
"       </td>",
"       <td class=\"centered\">",
"        Rettenbacher T, et al",
"       </td>",
"       <td class=\"centered\">",
"        2003",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        125",
"       </td>",
"       <td class=\"centered\">",
"        83",
"       </td>",
"       <td class=\"centered\">",
"        95",
"       </td>",
"       <td class=\"centered\">",
"        NE",
"       </td>",
"       <td class=\"centered\">",
"        NE",
"       </td>",
"       <td class=\"centered\">",
"        [9]",
"       </td>",
"       <td class=\"centered\">",
"        Kessler N, et al",
"       </td>",
"       <td class=\"centered\">",
"        2004",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        174",
"       </td>",
"       <td class=\"centered\">",
"        83",
"       </td>",
"       <td class=\"centered\">",
"        95",
"       </td>",
"       <td class=\"centered\">",
"        86",
"       </td>",
"       <td class=\"centered\">",
"        94",
"       </td>",
"       <td class=\"centered\">",
"        [10]",
"       </td>",
"       <td class=\"centered\">",
"        Chan I, et al",
"       </td>",
"       <td class=\"centered\">",
"        2005",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        MA",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td class=\"centered\">",
"        88",
"       </td>",
"       <td class=\"centered\">",
"        94",
"       </td>",
"       <td class=\"centered\">",
"        NE",
"       </td>",
"       <td class=\"centered\">",
"        NE",
"       </td>",
"       <td class=\"centered\">",
"        [11]",
"       </td>",
"       <td class=\"centered\">",
"        Doria AS, et al",
"       </td>",
"       <td class=\"centered\">",
"        2006",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        MA",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td class=\"centered\">",
"        83",
"       </td>",
"       <td class=\"centered\">",
"        93",
"       </td>",
"       <td class=\"centered\">",
"        NE",
"       </td>",
"       <td class=\"centered\">",
"        NE",
"       </td>",
"       <td class=\"centered\">",
"        [11]",
"       </td>",
"       <td class=\"centered\">",
"        Doria AS, et al",
"       </td>",
"       <td class=\"centered\">",
"        2006",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        MA",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"       <td class=\"centered\">",
"        87",
"       </td>",
"       <td class=\"centered\">",
"        89",
"       </td>",
"       <td class=\"centered\">",
"        NE",
"       </td>",
"       <td class=\"centered\">",
"        NE",
"       </td>",
"       <td class=\"centered\">",
"        [12]",
"       </td>",
"       <td class=\"centered\">",
"        Klein MD",
"       </td>",
"       <td class=\"centered\">",
"        2007",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        420",
"       </td>",
"       <td class=\"centered\">",
"        74",
"       </td>",
"       <td class=\"centered\">",
"        97",
"       </td>",
"       <td class=\"centered\">",
"        88",
"       </td>",
"       <td class=\"centered\">",
"        93",
"       </td>",
"       <td class=\"centered\">",
"        [13]",
"       </td>",
"       <td class=\"centered\">",
"        Gaitini D, et al",
"       </td>",
"       <td class=\"centered\">",
"        2008",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        132",
"       </td>",
"       <td class=\"centered\">",
"        65",
"       </td>",
"       <td class=\"centered\">",
"        90",
"       </td>",
"       <td class=\"centered\">",
"        84",
"       </td>",
"       <td class=\"centered\">",
"        76",
"       </td>",
"       <td class=\"centered\">",
"        [14]",
"       </td>",
"       <td class=\"centered\">",
"        Fox JC, et al",
"       </td>",
"       <td class=\"centered\">",
"        2008",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        33",
"        <sup>",
"         &sect;",
"        </sup>",
"       </td>",
"       <td class=\"centered\">",
"        50",
"       </td>",
"       <td class=\"centered\">",
"        100",
"       </td>",
"       <td class=\"centered\">",
"        100",
"       </td>",
"       <td class=\"centered\">",
"        66",
"       </td>",
"       <td class=\"centered\">",
"        [15]",
"       </td>",
"       <td class=\"centered\">",
"        Israel GM, et al",
"       </td>",
"       <td class=\"centered\">",
"        2008",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        121",
"        <sup>",
"         &yen;",
"        </sup>",
"       </td>",
"       <td class=\"centered\">",
"        90",
"       </td>",
"       <td class=\"centered\">",
"        93",
"       </td>",
"       <td class=\"centered\">",
"        NE",
"       </td>",
"       <td class=\"centered\">",
"        NE",
"       </td>",
"       <td class=\"centered\">",
"        [16]",
"       </td>",
"       <td class=\"centered\">",
"        Je BK, et al",
"       </td>",
"       <td class=\"centered\">",
"        2009",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        121",
"        <sup>",
"         ",
"        </sup>",
"       </td>",
"       <td class=\"centered\">",
"        85",
"       </td>",
"       <td class=\"centered\">",
"        96",
"       </td>",
"       <td class=\"centered\">",
"        NE",
"       </td>",
"       <td class=\"centered\">",
"        NE",
"       </td>",
"       <td class=\"centered\">",
"        [16]",
"       </td>",
"       <td class=\"centered\">",
"        Je BK, et al",
"       </td>",
"       <td class=\"centered\">",
"        2009",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        162",
"        <sup>",
"         ",
"        </sup>",
"       </td>",
"       <td class=\"centered\">",
"        87",
"       </td>",
"       <td class=\"centered\">",
"        46",
"       </td>",
"       <td class=\"centered\">",
"        49",
"       </td>",
"       <td class=\"centered\">",
"        85",
"       </td>",
"       <td class=\"centered\">",
"        [17]",
"       </td>",
"       <td class=\"centered\">",
"        Schuh S, et al",
"       </td>",
"       <td class=\"centered\">",
"        2010",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        193",
"       </td>",
"       <td class=\"centered\">",
"        81",
"       </td>",
"       <td class=\"centered\">",
"        88",
"       </td>",
"       <td class=\"centered\">",
"        61",
"       </td>",
"       <td class=\"centered\">",
"        95",
"       </td>",
"       <td class=\"centered\">",
"        [18]",
"       </td>",
"       <td class=\"centered\">",
"        Pacharn P, et al",
"       </td>",
"       <td class=\"centered\">",
"        2010",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        204",
"        <sup>",
"         ",
"        </sup>",
"       </td>",
"       <td class=\"centered\">",
"        99",
"       </td>",
"       <td class=\"centered\">",
"        95",
"       </td>",
"       <td class=\"centered\">",
"        NE",
"       </td>",
"       <td class=\"centered\">",
"        NE",
"       </td>",
"       <td class=\"centered\">",
"        [19]",
"       </td>",
"       <td class=\"centered\">",
"        Goldin AB, et al",
"       </td>",
"       <td class=\"centered\">",
"        2011",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        147",
"        <sup>",
"         ",
"        </sup>",
"       </td>",
"       <td class=\"centered\">",
"        38",
"       </td>",
"       <td class=\"centered\">",
"        97",
"       </td>",
"       <td class=\"centered\">",
"        NE",
"       </td>",
"       <td class=\"centered\">",
"        NE",
"       </td>",
"       <td class=\"centered\">",
"        [20]",
"       </td>",
"       <td class=\"centered\">",
"        Abo A, et al",
"       </td>",
"       <td class=\"centered\">",
"        2011",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     PPV: positive predictive value; NPV: negative predictive value; NE: not evaluable.",
"     <br/>",
"     * Age &gt;50 years old.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     Meta-analysis in children, 26 studies, 9356 patients.",
"     <br/>",
"     &Delta; Meta-analysis in adults, 31 studies, 4341 patients.",
"     <br/>",
"     <span class=\"lozenge\">",
"      &loz;",
"     </span>",
"     Meta-analysis, 9 studies.",
"     <br/>",
"     &sect; Pregnant women.",
"     <br/>",
"     &yen; Criterion is the maximal-outer-diameter (MOD) &gt;0.57 mm.",
"     <br/>",
"      Criterion is the maximal-mural-thickness (MMT) &gt;0.22 mm.",
"     <br/>",
"      Children.",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br>",
"      <ol>",
"       <li>",
"        Vignault F, Filiatrault D, Brandt ML, Garel L, Grignon A, Ouimet A. Acute appendicitis in children: evaluation with US. Radiology 1990; 176:501.",
"       </li>",
"       <li>",
"        Schwerk WB, Wichtrup B, Ruschoff J, Rothmund M. Acute and perforated appendicitis: current experience with ultrasound-aided diagnosis. World J Surg 1990; 14:271.",
"       </li>",
"       <li>",
"        Bendeck SE, Nino-Murcia M, Berry GJ, Jeffrey RB, Jr. Imaging for suspected appendicitis: negative appendectomy and perforation rates. Radiology 2002; 225:131.",
"       </li>",
"       <li>",
"        Kaiser S, Frenckner B, Jorulf HK. Suspected appendicitis in children: US and CT--a prospective randomized study. Radiology 2002; 223:633.",
"       </li>",
"       <li>",
"        Sun SS, Wu HS, Wang JJ, Ho ST, Kao A. Comparison between technetium 99m hexamethylpropyleneamine oxide labeled white blood cell abdominal scan and abdominal sonography to detect appendicitis in adult patients with atypical clinical presentation. Abdom Imaging 2002; 27:734.",
"       </li>",
"       <li>",
"        Chang CC, Tsai CY, Lin CC, Jeng LB, Lee CC, Kao CH. Comparison between technetium-99m hexamethylpropyleneamineoxide labeled white blood cell abdomen scan and abdominal sonography to detect appendicitis in children with an atypical clinical presentation. Hepatogastroenterology 2003; 50:426.",
"       </li>",
"       <li>",
"        Poortman P, Lohle PN, Schoemaker CM, Oostvogel HJ, Teepen HJ, Zwinderman KA et al. Comparison of CT and sonography in the diagnosis of acute appendicitis: a blinded prospective study. AJR Am J Roentgenol 2003; 181:1355.",
"       </li>",
"       <li>",
"        Rettenbacher T, Hollerweger A, Macheiner P, Gritzmann N, Daniaux M, Schwamberger K et al. Ovoid shape of the vermiform appendix: a criterion to exclude acute appendicitis--evaluation with US. Radiology 2003; 226:95.",
"       </li>",
"       <li>",
"        Kessler N, Cyteval C, Gallix B, Lesnik A, Blayac PM, Pujol J et al. Appendicitis: evaluation of sensitivity, specificity, and predictive values of US, Doppler US, and laboratory findings. Radiology 2004; 230:472.",
"       </li>",
"       <li>",
"        Chan I, Bicknell SG, Graham M. Utility and diagnostic accuracy of sonography in detecting appendicitis in a community hospital. AJR Am J Roentgenol 2005; 184:1809.",
"       </li>",
"       <li>",
"        Doria AS, Moineddin R, Kellenberger CJ, Epelman M, Beyene J, Schuh S et al. US or CT for Diagnosis of Appendicitis in Children and Adults? A Meta-Analysis. Radiology 2006; 241:83.",
"       </li>",
"       <li>",
"        Klein MD. Clinical approach to a child with abdominal pain who might have appendicitis. Pediatr Radiol 2007; 37:11.",
"       </li>",
"       <li>",
"        Gaitini D, Beck-Razi N, Mor-Yosef D, Fischer D, Ben Itzhak O, Krausz MM, Engel A. Diagnosing acute appendicitis in adults: accuracy of color Doppler sonography and MDCT compared with surgery and clinical follow-up. AJR Am J Roentgenol. 2008; 190:1300.",
"       </li>",
"       <li>",
"        Fox JC, Solley M, Anderson CL, Zlidenny A, Lahham S, Maasumi K. Prospective evaluation of emergency physician performed bedside ultrasound to detect acute appendicitis. Eur J Emerg Med. 2008; 15:80.",
"       </li>",
"       <li>",
"        Israel GM, Malguria N, McCarthy S, Copel J, Weinreb J. MRI vs. ultrasound for suspected appendicitis during pregnancy. J Magn Reson Imaging. 2008; 28:428.",
"       </li>",
"       <li>",
"        Je BK, Kim SB, Lee SH, Lee KY, Cha SH. Diagnostic value of maximal-outer-diameter and maximal-mural-thickness in use of ultrasound for acute appendicitis in children. World J Gastroenterol. 2009; 15:2900.",
"       </li>",
"       <li>",
"        Schuh S, Man C, Cheng A, Murphy A, Mohanta A, Moineddin R, Tomlinson G, Langer JC, Doria AS. Predictors of non-diagnostic ultrasound scanning in children with suspected appendicitis. J Pediatr. 2011; 158:112.",
"       </li>",
"       <li>",
"        Pacharn P, Ying J, Linam LE, Brody AS, Babcock DS. Sonography in the evaluation of acute appendicitis: are negative sonographic findings good enough? J Ultrasound Med. 2010; 29:1749.",
"       </li>",
"       <li>",
"        Goldin AB, Khanna P, Thapa M, McBroom JA, Garrison MM, Parisi MT. Revised ultrasound criteria for appendicitis in children improve diagnostic accuracy. Pediatr Radiol. 2011; 41:993.",
"       </li>",
"       <li>",
"        Abo A, Shannon M, Taylor G, Bachur R. The influence of body mass index on the accuracy of ultrasound and computed tomography in diagnosing appendicitis in children. Pediatr Emerg Care. 2011; 27:731.",
"       </li>",
"      </ol>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_48_20239=[""].join("\n");
var outline_f19_48_20239=null;
